Clinical Utility of Viral Load in Management of Cytomegalovirus Infection after Solid Organ Transplantation

Raymund R. Razonable, Randall T. Hayden

Division of Infectious Diseases, Department of Medicine, and the William J. von Liebig Transplant Center, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA; Department of Pathology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA

SUMMARY
The negative impact of cytomegalovirus (CMV) infection on transplant outcomes warrants efforts toward improving its prevention, diagnosis, and treatment. During the last 2 decades, significant breakthroughs in diagnostic virology have facilitated remarkable improvements in CMV disease management. During this period, CMV nucleic acid amplification testing (NAT) evolved to become one of the most commonly performed tests in clinical virology laboratories. NAT provides a means for rapid and sensitive diagnosis of CMV infection in transplant recipients. Viral quantification also introduced several principles of CMV disease management. Specifically, viral load has been utilized (i) for prognostication of CMV disease, (ii) to guide preemptive therapy, (iii) to assess the efficacy of antiviral treatment, (iv) to guide the duration of treatment, and (v) to indicate the risk of clinical relapse or antiviral drug resistance. However, there remain important limitations that require further optimization, including the interassay variability in viral load reporting, which has limited the generation of standardized viral load thresholds for various clinical indications. The recent introduction of an international reference standard should advance the major goal of uniform viral load.

Address correspondence to Raymund R. Razonable, Razonable.raymund@mayo.edu, or Randall T. Hayden, Randall.Hayden@stjude.org.

Copyright © 2013, American Society for Microbiology. All Rights Reserved.
reporting and interpretation. However, it has also become apparent that other aspects of NAT should be standardized, including sample selection, nucleic acid extraction, amplification, detection, and calibration, among others. This review article synthesizes the vast amount of information on CMV NAT and provides a timely review of the clinical utility of viral load testing in the management of CMV in solid organ transplant recipients. Current limitations are highlighted, and avenues for further research are suggested to optimize the clinical application of NAT in the management of CMV after transplantation.

INTRODUCTION

Cytomegalovirus (CMV) is one of the most common pathogens that infect solid organ transplant (SOT) recipients (1). The impact of CMV on the outcome of SOT is enormous—the virus not only causes a highly morbid and potentially fatal illness but also indirectly influences other relevant outcomes, such as allograft rejection, risk of other opportunistic infections, and overall patient and allograft survival (1). Because of the magnitude of its direct and indirect impacts, there have been extraordinary efforts aimed at defining strategies for its prevention and treatment.

Critical to improving the management of CMV infection after SOT have been the remarkable advances in clinical virology. During the last 2 decades, significant breakthroughs in diagnostic virology have paralleled and facilitated improvements in CMV disease management (2). In particular, CMV diagnostics has been transformed from the use of laborious methods of cell culture, first to the more sensitive method of direct antigen testing and subsequently to the widespread use of viral load testing (reviewed in reference 2). During this period, nucleic acid amplification testing (NAT) moved from the realm of research laboratories to become one of the most commonly performed tests in clinical virology laboratories (2).

NAT provides a means for rapid and sensitive diagnosis of CMV infection in SOT recipients (2). The “real-time” nature of CMV NAT is of utmost importance in the management of the most immunocompromised patients by allowing rapid laboratory confirmation of clinically suspected CMV infections. Moreover, NAT allows for quantification of the amount of CMV present per volume of clinical specimen (known as the viral load) (2). Indeed, the advent of viral quantitation introduced several principles that have transformed the way that CMV disease is prevented and treated. Specifically, viral load has been utilized (i) for prognostication of CMV disease (i.e., viral load is directly correlated with risk or severity of disease), (ii) to guide the need to initiate preemptive therapy, (iii) to assess the virological efficacy of antiviral treatment, (iv) to guide the duration of treatment, and (v) to indicate the risk of clinical relapse or antiviral drug resistance (1–3).

However, there remain important limitations to such testing, including the lack (until recently) of widely adopted quantitative standards (4, 5). Several platforms and methodologies are used for CMV NAT (2, 6), and in the absence of calibration to a common international reference standard, their performance could not be compared directly and accurately. Accordingly, universal viral load thresholds for various clinical indications (i.e., for guiding preemptive therapy, treatment responses, and the risk of relapse) have not been defined accurately. Numerous studies have reported viral load values for various clinical indications, but these remain specific to the assay, institution, and patient population used in a given study. To address this limitation, the World Health Organization released the first international standard for CMV quantitation, in 2010 (7). The availability of this standard should aid in the generation of potential viral load thresholds that are comparable across centers and widely applicable for different clinical applications. In addition, standardization of other aspects of NAT may still be needed to further improve the portability of viral load reporting. Viral load thresholds may need to be generated for various patient groups, since thresholds may vary depending on risk profiles.

In this article, we review the various methodologies for CMV diagnosis, with particular emphasis on CMV NAT. We synthesize the vast amount of information published to date on CMV NAT and provide a timely review of the clinical utility of CMV load testing in the management of SOT recipients. We highlight its current limitations and suggest avenues for research to further optimize the clinical application of NAT in the management of CMV after transplantation.

VIRAL EPIDEMIOLOGY AND MECHANISMS OF INFECTION

CMV infection is widespread and occurs worldwide. A recent epidemiologic survey in the United States reported an overall CMV seroprevalence of 50.4% (8). Other studies have described seroprevalence rates as high as 100% in some populations (9). Seroprevalence rates vary depending on age (higher rates are observed among older persons), geography (higher rates in developing countries), and socioeconomic status (higher rates in economically depressed regions) (8, 9).

CMV is acquired from exposure to saliva, tears, urine, stool, breast milk, semen, and other bodily secretions of infected individuals (10). Contact with contaminated environmental surfaces containing viable virus may also transmit the virus (10). CMV can also be acquired through blood transfusion and organ transplantation from CMV-infected donors (1, 11, 12).

Primary CMV infection occurs most commonly during the first 2 decades of life (13). In immunocompetent individuals, primary CMV infection is generally asymptomatic. In some patients, a benign self-limited febrile illness may ensue and last for several days. This febrile illness may be accompanied by generalized lymphadenopathy and may mimic the clinical illness of infectious mononucleosis (14).

Primary CMV infection induces a robust cellular and humoral immune response (15). CMV immunoglobulin M (CMV-IgM) is initially secreted during early CMV infection, and the detection of CMV-IgM by serologic assays is indicative of active, acute, or recent infection (16). Weeks into the course of primary infection, CMV-IgG antibody is secreted, and this antibody persists for life (16). The detection of CMV-IgG is indicative of previous or past infection (16). Durable control of CMV infection is the function of a robust cell-mediated immunity, with generation of CMV-specific CD4+ and CD8+ T cells (15, 17–19). Suppression of the number and function of CMV-specific CD4+ and CD8+ T cells allows for reactivation of the virus from latency, leading to uncontrolled viral replication and clinical disease in immunocompromised patients, including SOT recipients (15, 17, 18).

Several studies have demonstrated complex immune evasion mechanisms that circumvent the ability of humoral and cell-mediated immunity to eliminate CMV (20). Accordingly, primary CMV infection results in the virus entering a state of latency. The latent CMV genome has been demonstrated to be present in nu-
infection may be acquired from exposure to infected individuals in over 30% of all SOT recipients (3, 29–35). Much less commonly, primary CMV infection occurs in over 20% of SOT recipients (3) and is the single most important risk factor for the development of CMV disease in over 40% of patients with SOT (3, 29–43). The CMV virus is transmitted through organ donation to a susceptible individual, leading to high levels of viremia and clinically manifesting with systemic and, often, tissue-invasive illness (3, 27, 28). What controls the fate of CMV reactivation in these patients is the state of pathogen-specific immunity. Severely impaired CMV-specific immunity in a SOT recipient may permit uncontrolled viral replication, leading to high levels of viremia and clinically manifesting with systemic and, often, tissue-invasive illness (3, 27, 28).

Cells that harbor latent virus serve as primary vectors for transmission of CMV to susceptible individuals. Since latent CMV is widespread in almost every organ, its transmission through organ transplantation is very likely (3, 11, 12). In this context, primary infection occurs when a CMV-seropositive donor transmits the latent virus through organ donation to a susceptible CMV-seronegative transplant recipient (herein referred to as CMV D+/R−). The CMV D+/R− mismatch category occurs in an estimated 20 to 25% of all SOT recipients (3) and is the single most important risk factor for the development of CMV disease in SOT recipients (3, 29–35). Much less commonly, primary CMV infection may be acquired from exposure to infected individuals in the community (i.e., saliva and other body fluids) or through transfusion of blood from CMV-infected donors (3, 29). Because CMV-seronegative SOT recipients lack preexisting CMV-specific humoral and cell-mediated immunity, their ability to suppress viral reactivation (in the infected allograft) is nonexistent, thereby allowing for very rapid CMV replication dynamics. The growth rate has been calculated at 1.82 units/day (95% confidence interval [CI], 1.44 to 2.56 units/day) (36), which is commensurate to a doubling time of <2 days (Table 1) (3, 29–43). Clinically, this translates to a higher incidence and greater severity of CMV disease, characterized by high viral loads, among CMV D+/R− SOT recipients (3, 5, 36, 41–45).

Secondary CMV infection occurs in CMV-seropositive SOT recipients, as either reactivation or superinfection (reinfection) (3). Reactivation of endogenous latent CMV occurs after SOT in a CMV-seropositive patient, when CMV-specific immunity can be impaired by immunosuppressive drugs, especially T-lymphocyte-depleting compounds (17). In addition, superinfection (or reinfection) may occur when a CMV-seropositive recipient receives exogenous CMV from a CMV-seropositive donor, and subsequently, the circulating CMV may consist of both donor allograft-transmitted exogenous CMV and recipient-derived endogenous CMV (3). Differentiating reactivation from superinfection is not currently possible in routine clinical testing unless sophisticated genetic analyses are performed (46–48). Available studies indicate that superinfection occurs more commonly than reactivation of endogenous virus (46–49). CMV-seropositive recipients have preexisting CMV-specific humoral and cell-mediated immunity, and this immunologic memory can be mobilized during viral reactivation or reinfection. Such immunologic memory in CMV-seropositive transplant recipients damps CMV replication dynamics to a much lower rate (with a calculated growth rate of 0.61 unit/day [95% CI, 0.55 to 0.7 unit/day]) (36, 43). This is indicated by a relatively lower viral load (and lower rate of rise), which clinically translates into a typically lower incidence and reduced

### Table 1: Viral replication kinetics, incidence rates, and severity of CMV disease in solid organ transplant recipients

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value or description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viral replication kinetics (units/day) (mean [95% CI])</td>
<td>1.82 (1.44–2.56)</td>
</tr>
<tr>
<td>Viral doubling time (days) (mean [range])</td>
<td>1.54 (0.5–5.5)</td>
</tr>
<tr>
<td>Viral load at time of CMV disease diagnosis (absolute values dependent on specific viral load assay)</td>
<td>High to very high</td>
</tr>
<tr>
<td>Severity of CMV disease</td>
<td>Often moderate to severe</td>
</tr>
<tr>
<td>Incidence (%) of CMV disease in SOT organ</td>
<td>Often mild to moderate</td>
</tr>
<tr>
<td>Kidney and/or pancreas</td>
<td>No prophylaxis: 45–65; With prophylaxis: 6–38</td>
</tr>
<tr>
<td>Liver</td>
<td>No prophylaxis: 45–65; With prophylaxis: 6–29</td>
</tr>
<tr>
<td>Heart</td>
<td>No prophylaxis: 29–74; With prophylaxis: 17*</td>
</tr>
<tr>
<td>Lung and lung-heart</td>
<td>No prophylaxis: 50–91; With prophylaxis: 10*</td>
</tr>
<tr>
<td>Small bowel (intestinal)</td>
<td>No prophylaxis: LD; With prophylaxis: &lt;5–10*</td>
</tr>
<tr>
<td>Composite tissue (hand/face)</td>
<td>No prophylaxis: LD; With prophylaxis: 4**</td>
</tr>
</tbody>
</table>

* The risk of CMV disease is higher (i.e., rates at the higher end of the reported range) for CMV D+/R− patients than for CMV D−/R− solid organ transplant recipients. Rates are estimates based on a review of clinical trials and retrospective and prospective clinical studies. LD, limited data are available for intestinal and composite tissue transplant recipients.

Data were gathered from references 3 and 29 to 43.

** Prophylaxis is given for a duration of 3 months unless otherwise indicated. * 6 months of prophylaxis; ** 12 months of prophylaxis after lung transplantation. CMV disease in patients who receive prophylaxis generally occurs after the completion of antiviral prophylaxis (delayed-onset CMV disease).
severity of CMV disease (3, 43) (Table 1). However, CMV-seropositive SOT recipients who receive a high degree of immunosuppression, especially with agents that deplete T lymphocytes, may have much more rapid CMV replication dynamics, leading to a higher risk of disease (28, 50, 51).

**CLINICAL DISEASE**

CMV infection in SOT recipients exhibits a wide spectrum of clinical manifestations, from asymptomatic low-grade infection (typically associated with a low viral load) to severe, widely disseminated and potentially fatal CMV disease (characterized by a high viral load) (1, 3, 29). The clinical course of CMV infection and its presentation are influenced by several interrelated factors, including the degree of immunosuppression (1, 3, 29). In general, CMV disease manifests with greater severity in patients who lack or are deficient in CMV-specific immunity (17, 18, 27, 28, 52). Hence, CMV D+/R− SOT recipients have a higher incidence of infection and are predisposed to develop more severe forms of CMV disease (Table 1) (17, 18, 27, 28, 52). The predisposition to develop CMV disease is augmented by the use of intense pharmacologic immunosuppression, especially those agents that deplete T lymphocytes (27, 28, 53). CMV-seropositive SOT recipients who possess preexisting CMV-specific immunity have a relatively lower risk of CMV disease, and the occurrence of CMV disease in these patients is likely the result of the use of intense immunosuppression that severely impairs T cell function (17, 52). In all these cases, the risk of CMV disease and its severity can be correlated directly to viral load—in general, a higher viral load corresponds to a greater risk and severity of CMV disease (3, 5, 36, 41–45).

CMV infection in SOT recipients starts as local replication at sites that harbor latent virus. In CMV D+/R− SOT recipients, this typically means the transplanted allograft. Hence, allograft CMV infection in CMV D+/R− patients is not uncommon, and this may cause allograft dysfunction that can be mistaken as rejection (3, 28). In CMV-seropositive SOT recipients, local reactivation may occur anywhere, since the virus has widespread tissue distribution (54). If the virus is uncontrolled, local reactivation is followed by hematogenous dissemination (viremic phase). The vast majority of cases of CMV infection are diagnosed during this viremic phase, through viral load or antigen testing (3, 5, 36, 41–45).

SOT recipients with CMV disease may manifest with a syndrome characterized by fever, anorexia, myalgias, and arthralgias (3). This is often accompanied by leukopenia and thrombocytopenia (3). This clinical illness, termed CMV syndrome, is the most common clinical presentation of CMV disease in SOT recipients (Table 2) (3). The clinical diagnosis of CMV syndrome is confirmed by the demonstration of CMV in the blood (by either viral culture, antigen testing, or NAT) (3). In a smaller number of cases, CMV disease involves the invasion of end organs, and patients present with gastritis, enteritis, colitis, pneumonitis, encephalitis, hepatitis, nephritis, and carditis, among others. Virtually any organ system can be affected by CMV (1, 29, 55), but gastrointestinal involvement is the most common presentation of tissue-invasive CMV disease in SOT recipients (54). It can affect any segment of the gastrointestinal tract and manifests clinically as dysphagia, nausea, vomiting, abdominal pain, diarrhea, and gastrointestinal hemorrhage, depending on the site of involvement (54). Findings on endoscopy or colonoscopy include mucosal hyperemia, erosions, and ulcerations (54). Not uncommonly, CMV invasion may be localized to the transplanted allograft, such that pneumonitis, hepatitis, carditis, nephritis, and pancreatitis may be observed among lung, liver, heart, kidney, and pancreas transplant recipients, respectively (1, 29). Ideally, the diagnosis of tissue-invasive CMV disease should be supported by biopsy and histopathology. However, clinicians are sometimes hesitant to perform invasive procedures to obtain tissue for diagnosis. Hence, in the presence of appropriate signs and symptoms, the clinical diagnosis of tissue-invasive CMV disease may be suggested by the detection of CMV in the blood by culture, antigen testing, or NAT (3). The correlation between these blood tests and the diagnosis of CMV disease has led to a decline in obtaining tissue to confirm tissue-invasive CMV diseases (1, 29). However, the detection of CMV in the blood does not necessarily exclude the presence of copathogens or concomitant conditions, such as allograft rejection. Indeed, the clinical manifestations of CMV disease involving the transplanted allograft may be nonspecific and difficult to differentiate from allograft rejection (28). It therefore remains necessary for tissue biopsy to be performed for definitive diagnosis given clinical suspicion and unresponsiveness to antiviral treatment. Conversely, the absence of CMV in the blood of these patients does not totally exclude CMV disease as a diagnosis, as some cases of compartmentalized or localized CMV diseases have very low or transient periods of viremia (1, 3, 29).

The impact of CMV on SOT also encompasses numerous in-

<table>
<thead>
<tr>
<th>TABLE 2</th>
<th>Clinical manifestations and impact of CMV infection after solid organ transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effect</td>
<td></td>
</tr>
<tr>
<td>Direct</td>
<td></td>
</tr>
<tr>
<td>CMV syndrome—most common clinical manifestation</td>
<td></td>
</tr>
<tr>
<td>Tissue-invasive CMV disease</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal disease—most common organ involvement</td>
<td></td>
</tr>
<tr>
<td>Allograft infection</td>
<td></td>
</tr>
<tr>
<td>Hepatitis</td>
<td></td>
</tr>
<tr>
<td>Pneumonitis</td>
<td></td>
</tr>
<tr>
<td>Nephritis</td>
<td></td>
</tr>
<tr>
<td>Pancreatitis</td>
<td></td>
</tr>
<tr>
<td>Carditis</td>
<td></td>
</tr>
<tr>
<td>CNS disease</td>
<td></td>
</tr>
<tr>
<td>Retinitis (rare)</td>
<td></td>
</tr>
<tr>
<td>Others (any organ can be infected by CMV)</td>
<td></td>
</tr>
<tr>
<td>Multiorgan disease</td>
<td></td>
</tr>
<tr>
<td>Mortality</td>
<td></td>
</tr>
<tr>
<td>Indirect</td>
<td></td>
</tr>
<tr>
<td>Acute allograft rejection</td>
<td></td>
</tr>
<tr>
<td>Chronic allograft rejection</td>
<td></td>
</tr>
<tr>
<td>Bronchiolitis obliterans</td>
<td></td>
</tr>
<tr>
<td>Coronary vasculopathy</td>
<td></td>
</tr>
<tr>
<td>Tubulointerstitial fibrosis</td>
<td></td>
</tr>
<tr>
<td>Vanishing bile duct syndrome</td>
<td></td>
</tr>
<tr>
<td>Opportunistic and other infections</td>
<td></td>
</tr>
<tr>
<td>Fungal superinfection</td>
<td></td>
</tr>
<tr>
<td>Bacterial superinfection</td>
<td></td>
</tr>
<tr>
<td>Epstein-Barr virus-associated PTLD</td>
<td></td>
</tr>
<tr>
<td>Hepatitis C recurrence</td>
<td></td>
</tr>
<tr>
<td>Infections with other viruses (e.g., HHV-6 and HHV-7)</td>
<td></td>
</tr>
<tr>
<td>Increased risk of death</td>
<td></td>
</tr>
</tbody>
</table>

* CMV, cytomegalovirus; PTLD, posttransplant lymphoproliferative disease; HHV, human herpesvirus.
obtain tissue samples from patients clinically suspected to have gastrointestinal tissue-invasive CMV disease (54). Bronchoscopy may be needed to obtain respiratory fluid and tissue for the diagnosis of CMV pneumonia (73). Allograft biopsy may be needed to document allograft tissue invasion by CMV and to rule out other causes of allograft dysfunction (3). Because these procedures are invasive, clinicians are often hesitant to perform them. Moreover, repeated biopsies are generally not performed serially to assess the response to treatment (54). Accordingly, many clinicians rely on the demonstration of CMV in the peripheral blood by NAT or antigen testing to support the clinical diagnosis of tissue-invasive CMV disease in patients with compatible clinical signs and symptoms. For example, SOT patients presenting with diarrhea are presumed to have tissue-invasive gastrointestinal CMV disease if a high CMV load is concomitantly demonstrated (3). Likewise, CMV pneumonia is probable in a patient with respiratory symptoms, radiographic findings, and presence of CMV in the blood, especially if a high viral load is observed (3).

Histopathology of an allograft biopsy specimen is highly recommended if allograft rejection is a diagnostic consideration in a patient with CMV viremia (3). It is also recommended when it is critical to distinguish CMV disease from other conditions or co-pathogens, especially when anti-CMV treatment does not lead to complete resolution of clinical symptoms (3, 74). Histopathology is also required in cases of compartmentalized or localized CMV disease when CMV testing of the blood is negative (3).

Serology

Principle and methods. Serology relies on the sensitive detection of antibodies against CMV in the blood (3, 16). Several methodologies are available for antibody detection, but the most commonly used is the enzyme-linked immunosorbent assay (ELISA), for which there are various commercial products available (16).

Clinical applications. The main clinical utility of CMV serology in transplantation is in the pretransplant screening of organ (and blood) donors and transplant candidates (3). The detection of CMV-IgG is recommended, but IgM testing is discouraged due to frequent false-positive results. Knowledge of the CMV-IgG serostatus of the donor and recipient guides the stratification of SOT patients into different categories of CMV disease risk after transplantation (3). The high-risk category includes CMV D+/R− patients, the moderate-risk category includes CMV D+/R+ and CMV D−/R+ patients, and the low-risk category includes CMV D−/R− patients (3). Depending on the risk category, the recommended prevention measures vary, with either antiviral prophylaxis or preemptive therapy guided by antigen testing or CMV NAT.

CMV-IgM and -IgG antibody testing is generally not recommended for the diagnosis of active CMV infection or disease in SOT recipients (3). It is also not used to monitor the clinical course of infection or response to treatment. Because of drug-induced immune suppression, SOT recipients have a delayed or impaired ability to develop antibody responses, thereby limiting the clinical utility of serology for real-time diagnosis of acute CMV infection (3). Previous studies have shown the lack of timely serologic conversion in transplant recipients with CMV infection (70).

The clinical utility of CMV serologic testing to assess seroconversion (or lack thereof) in CMV D+/R− SOT recipients has been assessed as a potential predictor of late-onset CMV disease. Seroconversion at the completion of a 3-month antiviral prophylaxis in...
<table>
<thead>
<tr>
<th>Method</th>
<th>Principle</th>
<th>Sample type or processing details</th>
<th>Turnaround time</th>
<th>Results and clinical utility</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Non-nucleic acid-based methods</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serology</td>
<td>Detection of antibody against CMV (IgG, IgM)</td>
<td>Serum</td>
<td>6 h</td>
<td>CMV-IgG indicates past CMV infection (latent infection); CMV-IgM implies acute or recent infection</td>
<td>Prognostication and risk assignment of patients and their donors prior to transplantation (CMV D+/−, D+/ R−, D−/R+, or D−/R−)</td>
<td>Not useful for CMV disease diagnosis in transplant recipients due to attenuated and delayed antibody production; not useful for guiding duration of treatment</td>
</tr>
<tr>
<td>Histopathology</td>
<td>Demonstration of CMV-infected cells (enlarged cells with nuclear inclusions)</td>
<td>Tissue microscopy with H&amp;E stain; may need <em>in situ</em> hybridization and immunohistochemical staining to increase sensitivity and specificity</td>
<td>24–48 h</td>
<td>Detection of CMV-infected cells indicates active tissue-invasive disease</td>
<td>Confirmatory test for tissue-invasive CMV disease; highly specific</td>
<td>Need for invasive method to obtain tissue specimen; not generally used to monitor treatment response or risk of relapse</td>
</tr>
<tr>
<td>Virus culture</td>
<td>Viral growth in human fibroblast cells is indicated by CPE</td>
<td>Cell culture facility; light microscopy</td>
<td>2–4 weeks</td>
<td>Detection of characteristic CPE indicates presence of virus</td>
<td>Highly specific for CMV infection; the viral isolate can be tested for phenotypic susceptibility</td>
<td>Prolonged processing time is not clinically useful in real-time clinical management; poor sensitivity; requires viable CMV; not generally used to monitor treatment response or risk of relapse</td>
</tr>
<tr>
<td>Tube culture</td>
<td>Viral growth in human fibroblast cells is indicated by CPE</td>
<td>Cell culture facility; light microscopy</td>
<td>2–4 weeks</td>
<td>Detection of characteristic CPE indicates presence of virus</td>
<td>Highly specific for CMV infection; the viral isolate can be tested for phenotypic susceptibility</td>
<td>Prolonged processing time is not clinically useful in real-time clinical management; poor sensitivity; requires viable CMV; not generally used to monitor treatment response or risk of relapse</td>
</tr>
<tr>
<td><strong>Shell vial assay</strong></td>
<td>Viral growth with detection using monoclonal antibodies against viral antigens</td>
<td>Cell culture facility; immunofluorescence detection</td>
<td>16–48 h</td>
<td>Infectious foci detected by monoclonal antibody directed to immediate-early antigen of CMV (prior to the onset of CPE)</td>
<td>Highly specific for CMV infection; more sensitive and rapid than conventional tube cultures</td>
<td>Relatively low sensitivity compared to molecular methods; rapid decrease of CMV activity in clinical specimens; not generally used to monitor treatment response or risk of relapse; Subjective interpretation of results; requires rapid processing; not useful in leukopenic patients; lack of standardization in no. of positive cells for various clinical indications</td>
</tr>
<tr>
<td><strong>Antigenemia assay</strong></td>
<td>Detection of pp65 antigen</td>
<td>Polymorphonuclear cells; processing within 4–6 h; light microscopy or immunofluorescence</td>
<td>6 h</td>
<td>Number of CMV-infected cells per total number of cells (e.g., 5 × 10^3)</td>
<td>Rapid diagnosis of CMV infection; quantification (no. of positive cells) may indicate disease and infection severity, may be used as a guide for preemptive therapy, and may be used as a guide for treatment response and duration of treatment</td>
<td>Subjective interpretation of results; requires rapid processing; not useful in leukopenic patients; lack of standardization in no. of positive cells for various clinical indications</td>
</tr>
<tr>
<td><strong>Nucleic acid-based molecular methods</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nucleic acid amplification tests</strong></td>
<td>PCR amplification and detection of CMV DNA or RNA</td>
<td>Various clinical samples (blood, other body fluids); various assays (commercial and laboratory-developed tests)</td>
<td>Few hours</td>
<td>Standardized assay results reported as IU/ml; nonstandardized assay results reported as no. of CMV copies per volume of specimen or PCR</td>
<td>Highly sensitive and specific for rapid diagnosis of CMV; quantification (viral load) allows for individualized management of patients; used to indicate disease severity; used to guide preemptive therapy; used to assess the risk of CMV disease; used to guide duration of antiviral treatment; used as surrogate of disease relapse or infection with resistant virus</td>
<td>Currently without a widely accepted viral threshold for predicting CMV disease; lack of assay standardization limits portability of results—ongoing efforts at assay standardization may reduce this limitation; highly sensitive assay may detect latent CMV</td>
</tr>
<tr>
<td><strong>NucliSens pp67 test</strong></td>
<td>mRNA detection</td>
<td>Whole blood; samples must be processed within 24 h (or kept in lysis buffer at −80°C indefinitely)</td>
<td>6 h</td>
<td>Qualitative assay for detection of active CMV infection</td>
<td>Highly specific for viral replication, since it measures the replicative intermediate; clinical utility for preemptive therapy; clinical utility for monitoring response to treatment</td>
<td>Qualitative assay; less sensitive than nucleic acid amplification tests</td>
</tr>
<tr>
<td><strong>Hybrid capture assay</strong></td>
<td>DNA-RNA hybrid</td>
<td>Whole blood; delayed processing is possible</td>
<td>6 h</td>
<td>No. of CMV copies per ml (lowest limit of detection, 7 × 10^3 copies per ml of whole blood)</td>
<td>Highly specific for CMV infection; rapid diagnosis of CMV infection</td>
<td>Less sensitive than nucleic acid amplification tests</td>
</tr>
</tbody>
</table>

*CMV, cytomegalovirus; CPE, cytopathic effects; H&E, hematoxylin and eosin.*
CMV D+ / R – SOT recipients was not significantly associated with protection from late-onset CMV disease (75). In contrast, the detection of CMV-IgG at 6 months (in patients who received 3 months of antiviral prophylaxis) was associated with a lower risk of late-onset CMV disease, although the clinical benefit for this is tempered by the fact that most CMV disease cases occurred prior to the 6th month after transplantation (75). Accordingly, current guidelines do not strongly recommend the use of CMV serology during the posttransplant period to guide treatment duration or discontinuation of antiviral prophylaxis, as there are currently no solid data to support this clinical application (3).

Culture

Principle, assay characteristics, clinical applications, and limitations. Viral culture is highly specific for the diagnosis of CMV infection in SOT recipients (3, 70). Culture can be performed using the conventional plaque assay or the more rapid shell vial centrifugation culture system (2). Viral culture can be performed on blood, respiratory secretions (including bronchoalveolar lavage [BAL] fluid), saliva, urine, stool, cerebrospinal fluid (CSF), and tissue biopsy specimens. Isolation of CMV from most clinical samples (other than urine, saliva, and stool) is highly predictive of the diagnosis of CMV disease or the risk of progression from CMV infection into clinical illness (2, 76, 77). In contrast, the use of urine, saliva, and stool samples for CMV culture is of limited clinical utility because viral shedding may be detected in these specimens in CMV-seropositive SOT recipients even in the absence of clinical illness (3). Urine, stool, and saliva are therefore not recommended as clinical samples for diagnostic purposes for most patients (3). For CMV-seronegative patients (seen most commonly in pediatric age groups), however, the isolation of CMV in urine (and other samples) may be clinically relevant, since it is suggestive of active primary infection (instead of shedding) (3). Indeed, the detection of CMV in the urine has been associated with a 2-fold higher risk of developing clinical CMV disease (76, 77).

The major drawbacks to viral culture are its low to modest sensitivity and long turnaround time (2, 3). Traditional tissue tube culture (plaque assay) requires the growth of CMV in human fibroblast cultures (MRC-5 cells). The presence of CMV is indicated by its typical cytopathic effect (CPE), characterized by foci of flat, swollen cells (2, 3). Notably, the time to the development of CPE has been correlated directly with the titer of CMV present in the sample. CPE has been detected as early as 2 days (in patients with high viral titers) or as late as 21 days (in patients with lower titers) after the start of culture. Because tube culture is very laborious and may take weeks for viral isolation and detection, its utility is very limited in contemporary clinical practice (2, 3). Its subsequent modification using the shell vial centrifugation technique has resulted in a shorter turnaround time (i.e., 48 h). Using the shell vial technique, cultured cells are stained by monoclonal antibodies to detect the presence of immediate-early antigens produced during viral replication (2, 3). This modification has allowed for the detection of CMV in cell culture prior to the development of CPE. Despite this modification, the test remains significantly much less sensitive than antigen detection and molecular assays (78–81). Accordingly, the clinical use of viral culture is minimal in the contemporary era, when molecular assays are most commonly used in the clinical setting (2, 3). The remaining major clinical use of viral culture is in the diagnosis of CMV infection by use of samples that have not been validated or optimized for molecular testing (2, 3). Viral culture may also be required when phenotypic antiviral drug resistance testing is needed, although advances in molecular genotypic assays have now emerged as methods of choice for detecting antiviral drug resistance (82).

Antigen Testing

Principle and assay characteristics. CMV antigen detection in the blood is the most commonly used phenotypic (nonmolecular) method for the rapid and sensitive diagnosis of CMV infection in SOT recipients (2, 3). CMV antigenemia assay uses monoclonal antibodies to detect the CMV lower matrix phosphoprotein pp65 antigen (encoded by UL83), a structural late protein expressed in CMV-infected leukocytes during the early phase of the CMV replication process (2, 3). The result of the test is reported as the number of positive cells per total number of cells counted (2, 3). Because pp65 is secreted during viral replication, its detection in peripheral blood leukocytes (PBL) generally signifies active CMV infection (83, 84).

The CMV antigen assay is a rapid and easy test to perform and has a higher sensitivity than that of virus culture (80, 85, 86). It is able to detect CMV infection earlier than virus culture, with some studies reporting the detection of antigenemia an average of 5 to 14 days before the onset of CMV disease (87, 88). In some studies, the sensitivity of pp65 antigenemia testing for the diagnosis of CMV infection was comparable to that of CMV NAT by PCR (78, 89–93). One of these studies reported a strong correlation between pp65 antigenemia and CMV PCR performed on whole-blood specimens by use of an in-house laboratory-developed test (LDT) (91). Other studies, however, have reported a significantly lower sensitivity of antigenemia testing than those of molecular tests (80, 88, 94–99). In one study, the sensitivity of pp65 antigenemia was lower (39%) than that of an ultraspread PCR-based assay performed on plasma (67%) (96). Moreover, the LDT plasma PCR assay detected CMV infection 12 days earlier than the antigenemia test (96). Another study reported a significantly lower sensitivity (26%) of pp65 antigenemia testing than those of two PCR-based assays (COBAS Amplicor CMV Monitor test [48.6%] and an in-house LDT [performed on a LightCycler] [54%]) (98). Similar observations were reported in a study that compared pp65 antigenemia testing with three different CMV PCR assays (each using different primer sets), using cell-free plasma samples (99).

Clinical applications. Detection of pp65-positive cells in the blood of a patient with compatible symptoms confirms the diagnosis of CMV disease (100, 101). The quantitative ability of pp65 antigenemia testing (i.e., the ability to quantify the viral burden based on the number of positive cells) may indicate the severity of CMV infection (84): the higher the number of pp65 antigen-positive cells, the greater is the disease severity or risk of progression to CMV disease.

CMV antigenemia can be used to detect early CMV replication and to guide the initiation of preemptive therapy. On average, antigenemia can be detected 5 to 14 days before the onset of CMV disease (102–105). Using this preemptive therapy approach for CMV disease prevention, SOT recipients are monitored regularly (usually once weekly) for the presence of pp65 antigen-positive cells in the blood. Once pp65 antigen-positive cells are detected at a predefined threshold (which varies depending on the institution and patient population), and prior to the onset of clinical symp-
toms, SOT patients are treated with antiviral drugs (most commonly with valganciclovir) in order to prevent the progression of asymptomatic CMV infection into clinical disease. In general, the degree of pp65 antigenemia correlates with the risk of subsequent CMV disease. However, there is a lack of consensus as to the threshold of pp65-positive cells that should trigger the initiation of antiviral therapy. One study recommended initiation of preemptive therapy once the number of pp65 antigen-positive cells exceeded 10 per 2 x 10⁵ cells counted. However, some studies have demonstrated that a patient with a small number of pp65-positive cells may still develop CMV disease, while some patients with larger numbers of positive cells resolve their infection spontaneously, without antiviral therapy (106). These divergent observations and the lack of a defined standardized threshold are likely due to the various risks among SOT recipients (highest among lung recipients and lower among kidney recipients), their preexisting CMV-specific immunity (highest among CMV D+/R− patients compared to others), and the severity of pharmacologic immunosuppression (highest with lymphocyte-depleting drugs) (83, 84, 88, 106–109).

CMV antigenemia has been used to guide antiviral treatment of CMV disease and to determine treatment endpoints (3, 95, 105). The number of pp65-positive leukocytes declines during the course of effective antiviral treatment (3). A few studies, however, have demonstrated that there may be intermittent rises in the level of antigenemia during the first 2 weeks of antiviral treatment (95, 105). The mechanism for this intermittent rise in antigenemia is not completely understood, but it does not necessarily suggest treatment failure as long the patient is clinically improving. Antiviral treatment is continued until pp65 antigenemia is no longer detected in the blood or has declined below a predefined threshold (3). A persistence or rise in the number of pp65-positive cells may indicate drug-resistant virus or the need to reduce immunosuppression as a component of antiviral therapy (3).

Limitations. The disadvantages of CMV antigenemia testing are its labor-intensive and manual nature (2). The interpretation of the test is subjective, and there is limited interlaboratory standardization of thresholds of positive cell counts to guide various clinical actions (2). Blood samples being subjected to pp65 antigenemia testing should be processed rapidly (ideally within 6 h) to optimize sensitivity, since test results depend on the life span of leukocytes ex vivo. Delays in the processing of a sample for longer than 24 h may lead to a significant decrease in the number of detectable pp65-positive cells in the blood (110, 111). Since the test relies on a sufficient number of polymorphonuclear leukocytes, the pp65 antigenemia assay has limited utility and may be falsely negative for patients with severe leukopenia, and it is not useful in relatively acellular samples, although it has been used to demonstrate the presence of CMV in BAL fluid (100, 101). Moreover, the use of NAT has continued to increase, displacing the use of antigenemia testing. Improvements in NAT, including efforts at standardization, may further increase its appeal, potentially leading to a continued decline in the clinical use of pp65 antigenemia testing.

Nucleic Acid-Based Methods

Nucleic acid amplification tests have emerged as the preferred methods for the rapid diagnosis of CMV after SOT (3). NAT assays are considered the most sensitive methods for CMV diagnosis, typically relying on PCR technology to detect minute amounts of viral nucleic acid in clinical samples. However, CMV persists in latent form in many nucleated cells; therefore, NAT has the risk of detecting and quantifying inactive, nonreplicating CMV. Laboratories should develop strategies aimed at distinguishing active viral infection from latent viral DNA detection. In the absence of such a discriminating test, the clinician is left to rely on clinical judgement in interpreting assay results and differentiating true infection from viral latency.

Several platforms are available for CMV NAT, and one has been approved by the U.S. Food and Drug Administration (CAP/CTM CMV test [Roche]) for viral load monitoring in patients receiving antiviral treatment for CMV disease (4, 5). The vast majority of CMV NAT assays are developed in-house (LDTs). LDTs are developed, optimized, and validated by each performing laboratory, and each has unique assay characteristics, such as the upper and lower limits of detection, linear range of detection, precision, and accuracy. The protocols for CMV NAT assays differ in many other aspects, including specimen types (blood, urine, CSF, BAL fluid, and others), blood sample preparations (whole blood, plasma, serum, and leukocytes), nucleic acid extraction methods, primers and targets (various CMV genes [DNA polymerase gene, glycoprotein B gene, immediate-early gene, major immediate-early gene, UL83, and others]), DNA versus RNA, quantitation standards and controls (versus qualitative assays), reaction and amplification protocols (e.g., number of cycles), signal generation systems, and methods for calculating copy numbers and reporting of results (2, 6, 97). In other words, all available CMV NAT assays were not created similarly, and their results are not interchangeable in the absence of standardization.

CMV DNA versus RNA as a target. As an enveloped double-stranded DNA virus, CMV produces viral mRNA transcripts during its replication cycle. In most CMV NAT assays, the target nucleic acid is DNA (2), although several assay have been developed to detect RNA through reverse transcriptase PCR (112).

Studies have consistently demonstrated that NAT to detect CMV DNA is a highly sensitive method of detecting CMV infection (2, 113). Because of its property of target amplification by the polymerase enzyme, CMV PCR has the ability to rapidly detect and quantify even small amounts of viral nucleic acid in clinical samples (113). CMV DNA is stable in clinical specimens over time, and delayed sample processing has not been associated with any major impact on CMV DNA quantification (111). A recent study demonstrated the stability of CMV DNA in EDTA-blood samples that had been stored at 4°C for 14 days (114). While it is a highly sensitive indicator of the presence of CMV in clinical samples, the detection of CMV DNA is a relatively less specific indicator (compared to RNA testing) of active CMV replication, as a highly sensitive CMV DNA test may detect inactive latent viral DNA (113). Indeed, CMV DNA has been detected by sensitive PCR in blood from otherwise healthy seropositive individuals (113). Detection of latent DNA may therefore lead to unnecessary antiviral treatment of patients without active CMV infection. Several CMV DNA targets have been used in various NAT assays, including the DNA polymerase gene and the glycoprotein B gene, among others. The amplification efficiencies of these DNA targets vary, resulting in noncomparable viral load results (6).

The concern of detecting latent CMV DNA has led to the development of assays that detect viral RNA targets. Because RNA intermediates are generally produced mainly during CMV replication and serve as the biologic link between the CMV genome
and gene expression, their detection should indicate active viral infection (115–119). Reverse transcriptase PCR is the method used to selectively detect viral mRNA transcripts in blood and other clinical specimens. However, RNA molecules are readily degraded, and their degradation in vitro can lead to false-negative results (115, 116). It is therefore important to safely transport and process clinical samples promptly. Compared to that of NAT detection of CMV DNA, the sensitivity of CMV RNA testing is lower (112). There have been several studies evaluating CMV mRNA in clinical samples as an indicator of CMV disease or risk of disease (94, 115, 116, 120). One study reported the presence of CMV immediate-early mRNA in leukocytes of transplant patients with active CMV infection (121). In another study, the presence of pp67 mRNA had 100% specificity for CMV disease, but it was detected only in patients with very high viral loads (94). Another study demonstrated that the presence of mRNA was more specific for CMV disease than CMV DNA detection (116). However, CMV RNA detection had a lower sensitivity than that of CMV DNA testing (122), and in some instances, it even showed a lower sensitivity than that of antigenemia testing (123).

**Qualitative and quantitative assays.** NAT assays can be developed as qualitative (reported as positive or negative) or quantitative (reported as the amount of virus, typically normalized to the volume of the input specimen) assays. Qualitative CMV DNA tests are highly sensitive for the diagnosis of CMV infection in SOT recipients (2, 124). In one study, the sensitivity of qualitative nested PCR in detecting CMV infection was reported to be as high as 95%, compared to only 83% for the TaqMan-based quantitative assay, with a threshold of >125,000 copies/2 × 10⁶ peripheral blood leukocytes (93). However, the specificity of qualitative NAT was dismal, and its positive predictive value was low compared to that of the quantitative assay (47% versus 68%) (93).

Qualitative CMV DNA tests do not reliably distinguish latent DNA from active viral replication. A qualitative CMV RNA test can offset this limitation, since detection of RNA intermediates is generally indicative of a replicating virus (112, 117, 118). Qualitative CMV DNA or RNA tests do not quantify viral loads, and hence they are not able to assess the severity of infection (2, 124). These tests are not able to differentiate low-level infection (associated with asymptomatic infection) from high-level viral replication (associated with CMV disease) (2, 124). Qualitative tests therefore have very limited clinical utility in disease prognostication and in monitoring antiviral treatment responses (2, 3). Qualitative tests cannot reliably be used to assess trends in the rise or decline of infection (2, 3); in one study, a qualitative CMV DNA test remained positive long after antiviral treatment was no longer required (93).

To increase the specificity of CMV DNA tests, laboratories have developed quantitative NAT (QNAT) and commonly report results in absolute values per volume of specimen or per PCR (2). Quantification of CMV DNA has correlated disease and infection severity with the degree of viral replication (i.e., viral load) (2, 3, 5, 36, 41–45). Active CMV replication is indicated by high absolute viral load values or a rising trend in viral loads, while low-level viral loads may indicate detection of latent viral DNA (2, 3, 5, 36, 41–45).

**Clinical samples.** (i) **Blood compartments.** NAT can detect CMV nucleic acid in various clinical specimens, although this is most commonly performed on peripheral blood samples (2, 114, 125–127). As discussed above, the pathogenesis of CMV infection results in its systemic spread through the blood (viremic phase). Hence, the majority of CMV disease can be diagnosed by demonstrating CMV nucleic acid in the blood (3).

CMV NAT using blood samples is highly sensitive for diagnosis of CMV infection (2, 114, 125–127). Different compartments of the blood have been used in the diagnosis of CMV infection, including leukocyte preparations, whole blood, plasma, and serum (2, 114, 125–127). Which of the various blood compartments is optimal for CMV DNA detection has been the subject of several studies (91, 126, 128). Overall, these studies have demonstrated that whole blood and leukocyte samples have the highest sensitivity for CMV DNA detection compared to plasma and serum (80, 91, 126, 128, 129). Whole blood is easy to process because it does not require complex sample preparation compared to preparation of leukocyte subpopulations (126). While studies have shown good correlations in viral load values among the various compartments, significantly higher viral load levels have been detected in whole blood (91, 126, 128, 130, 131). Accordingly, many authorities have advocated the use of whole blood for CMV DNA detection due to its higher sensitivity and ability to detect low-copy-number viral reactivation. In a study that compared 170 plasma and whole-blood samples obtained from 61 transplant recipients, 14% of the samples had discordant results (positive viral load in whole blood but negative result for plasma) (128). The majority of the discordant samples were observed at low viral load copy levels, implying the higher sensitivity of whole blood in detecting low-level viral loads (128). Some have suggested that using a highly sensitive sample will identify CMV disease in patients with low viral loads, but the specificity of detecting low-level CMV DNA in whole blood for predicting CMV disease is only modest (as some tests may detect latent virus). Moreover, many patients with low viral load values have a transient viremia that resolves spontaneously, and their detection may lead to unnecessary treatment. The use of a highly sensitive whole-blood PCR test may also lead to a longer course of antiviral therapy, since treatment is usually continued until CMV DNA is undetectable (128).

Because latent CMV may be detected and amplified in leukocyte-containing blood samples, the use of cell-free plasma or serum has been advocated by some as more indicative of active CMV infection in SOT recipients. There have been several studies showing a correlation between CMV infection and the viral load present in cell-free serum (132, 133) or plasma (80, 99, 126, 134). The source of CMV in plasma samples may be lysis of infected leukocytes or release from other infected sites, such as parenchymal and endothelial cells. Since CMV in plasma or serum may be due primarily to release from actively infected cells, it has been suggested that the detection of CMV in these samples is more specific for CMV infection than its detection in whole blood or peripheral blood leukocytes (whose CMV levels may be due to cell-associated latent CMV). Indeed, studies have demonstrated that detection of CMV DNA in plasma is highly associated with CMV disease (132, 133, 135).

The detection of CMV in blood specimens may be affected by the volume of whole blood, cells, or plasma samples used for processing and nucleic acid extraction. Theoretically, the sensitivity of NAT may vary among assays that utilize nucleic acid extracted from 0.2 ml of plasma or whole blood compared to larger sample volumes, especially when the viral load level is low. Such variability in viral load values based on sample volume may also be observed for other body fluids and tissues.
(ii) Cerebrospinal fluid. CSF analysis for CMV is indicated for patients presenting with compatible clinical symptoms of encephalitis, meningitis, polyarthritis, and others. CSF is a relatively acellular specimen, and the detection of CMV DNA by either qualitative or quantitative assay is highly suggestive of CMV central nervous system (CNS) disease (136–138). However, there should be cautious interpretation of CMV DNA results of qualitative tests, since significant pleocytosis (from inflammatory causes other than CMV disease) may result in falsely positive results due to detection of latent CMV in CSF leukocytes. Often, however, there are other clinical clues to the diagnosis of CMV CNS disease, such as magnetic resonance imaging (MRI) findings of periventricular enhancement. As in other cases, quantification has been advocated to assess the severity of clinical disease (in a study conducted in patients with AIDS) (136–138).

(iii) Aqueous and vitreous humor fluid. A detailed funduscopic examination by an experienced ophthalmologist can reliably diagnose CMV retinitis, which is characterized by retinal hemorrhages and a whitish granular appearance to the retina. The detection of CMV DNA in aqueous and vitreous fluid in these patients confirms the clinical diagnosis (139, 140). Obtaining vitreous fluid is also needed to exclude other potential etiologies, while others have used CMV NAT on vitreous fluid to monitor the efficacy of antiviral treatment responses (140).

(iv) Respiratory samples. The detection of CMV in BAL fluid may or may not be indicative of CMV pneumonia (68, 73, 141–145). Shedding of CMV in saliva and respiratory secretions is not uncommon, and the demonstration of CMV DNA in these respiratory samples in the absence of compatible clinical signs and symptoms (or in the absence of biopsy confirmation) is of unclear significance and does not necessarily indicate CMV pneumonia (141). In the presence of compatible clinical symptoms, however, the demonstration of CMV DNA may be helpful and may obviate risky lung biopsy in certain situations. Contamination by CMV that is shed in the saliva is a theoretical concern in the interpretation of BAL fluid NAT results, but a study of 76 simultaneously collected BAL fluid and throat wash samples from lung transplant recipients indicated that such contamination is unlikely and that demonstration of CMV DNA in the BAL fluid is highly representative of virus replication in the lung (144).

There have also been investigations to determine whether the degree of viral load is correlated with respiratory disease (141, 146). In a study of 27 lung transplant recipients, CMV loads of >500,000 copies/ml of BAL fluid were highly correlated with biopsy-proven CMV pneumonia (141). The viral load in the BAL fluid was also correlated with the severity of CMV lung tissue involvement, as measured by histopathologic findings and IHC staining (73). CMV NAT of BAL fluid has been suggested as a better marker of CMV pneumonia in lung recipients than CMV NAT of the blood, since sporadic cases of “compartmentalized” pneumonia without concomitant viremia have been reported (147). While CMV NAT of BAL fluid has been correlated highly with CMV disease in the lungs by some (148), others have found no correlation (149). Such discrepant results may be due to a lack of standardization in various aspects of sample collection and testing, including the amount of fluid effluent, sampling error, and assay performance characteristics. In addition, differences in patient risk profiles may account for the discrepant findings.

(v) Urine and other specimens. CMV can also be detected in urine and stool, although these are generally not recommended as samples for CMV disease diagnosis (3, 150, 151). Approximately 50% of transplant recipients excrete CMV in body secretions such as urine and stool at some stage after transplantation (152). Detection of CMV in these samples is therefore of minimal to modest clinical significance, as it does not necessarily indicate a high risk of clinical disease, particularly in CMV-seropositive transplant recipients. Detection of CMV DNA in urine is not specific for CMV disease of the genitourinary tract in adults, since CMV DNA is shed in the genitourinary system even in healthy individuals (3, 152).

The clinical utility of CMV DNA testing in the urine is in young infants, for whom serology may be difficult to interpret (due to the presence of maternal antibodies). The demonstration of CMV DNA in the urine of infants and children should indicate prior infection (and latency) or active infection (3). Demonstration of CMV DNA in the urine of any CMV D+/R− SOT recipient is also clinically significant, as it indicates true infection (3).

Assay variability, calibration, and standardization. One of the central issues that have emerged during the widespread application of CMV NAT in clinical practice is the significant interassay variability in viral load detection and quantification (4, 6, 97). Assays have differed in every aspect of design, including instrumentation, genetic detection targets (e.g., polymerase gene and glycoprotein B gene, among others), sample types (whole blood, plasma, and leukocytes), nucleic acid extraction methods, cycling parameters, detection chemistries and reagents, and reporting parameters (4, 6, 97).

Numerous investigators have highlighted the disparity of various CMV DNA tests, as exemplified by a few studies discussed here (2, 125, 153, 154). A comparative study of a TaqMan-based assay and another commercial real-time PCR assay (COBAS AmpliCord CMV Monitor test [Roche]) among 27 kidney and liver transplant patients demonstrated that while the results of the two assays were highly correlated, the TaqMan assay was more sensitive (92% versus 80% detection of all positive samples) and yielded higher viral load results (155). Another study compared the commercial COBAS AmpliCord CMV Monitor test (targeting the CMV DNA polymerase gene) and an LDT using a LightCycler instrument (targeting the glycoprotein B gene) and observed that viral load values from the LightCycler assay were significantly higher (98). In contrast, another group of investigators compared the same PCR systems but used a different target for the LDT LightCycler system, and they observed higher viral load values with the COBAS AmpliCord CMV Monitor test (125). The findings were consistent across blood compartments, with the COBAS AmpliCord CMV Monitor test reporting higher viral load results than the LDT for whole blood, plasma, peripheral blood leukocytes, and mononuclear cells (125). Another study comparing two generations of the LightCycler platform (version 2.0 and model 480 real-time PCR) further demonstrated that while the viral load results were highly correlated, there were statistically significant differences in the absolute viral load values reported by the instruments (156). The assays differed in both detection platform and probe chemistry (156), again suggesting factors that may play a role in interassay result variability.

The significant interassay and interlaboratory variability in viral load detection and reporting was highlighted by three recent multicenter trials that compared various CMV NAT assays. Potentially due to differences in assay platforms, clinical samples, calibrator standards, gene targets, extraction techniques, and

712 cmr.asm.org Clinical Microbiology Reviews

Razonable and Hayden

(ii) Cerebrospinal fluid. CSF analysis for CMV is indicated for patients presenting with compatible clinical symptoms of encephalitis, meningitis, polyarthritis, and others. CSF is a relatively acellular specimen, and the detection of CMV DNA by either qualitative or quantitative assay is highly suggestive of CMV central nervous system (CNS) disease (136–138). However, there should be cautious interpretation of CMV DNA results of qualitative tests, since significant pleocytosis (from inflammatory causes other than CMV disease) may result in falsely positive results due to detection of latent CMV in CSF leukocytes. Often, however, there are other clinical clues to the diagnosis of CMV CNS disease, such as magnetic resonance imaging (MRI) findings of periventricular enhancement. As in other cases, quantification has been advocated to assess the severity of clinical disease (in a study conducted in patients with AIDS) (136–138).

(iii) Aqueous and vitreous humor fluid. A detailed funduscopic examination by an experienced ophthalmologist can reliably diagnose CMV retinitis, which is characterized by retinal hemorrhages and a whitish granular appearance to the retina. The detection of CMV DNA in aqueous and vitreous fluid in these patients confirms the clinical diagnosis (139, 140). Obtaining vitreous fluid is also needed to exclude other potential etiologies, while others have used CMV NAT on vitreous fluid to monitor the efficacy of antiviral treatment responses (140).

(iv) Respiratory samples. The detection of CMV in BAL fluid may or may not be indicative of CMV pneumonia (68, 73, 141–145). Shedding of CMV in saliva and respiratory secretions is not uncommon, and the demonstration of CMV DNA in these respiratory samples in the absence of compatible clinical signs and symptoms (or in the absence of biopsy confirmation) is of unclear significance and does not necessarily indicate CMV pneumonia (141). In the presence of compatible clinical symptoms, however, the demonstration of CMV DNA may be helpful and may obviate risky lung biopsy in certain situations. Contamination by CMV that is shed in the saliva is a theoretical concern in the interpretation of BAL fluid NAT results, but a study of 76 simultaneously collected BAL fluid and throat wash samples from lung transplant recipients indicated that such contamination is unlikely and that demonstration of CMV DNA in the BAL fluid is highly representative of virus replication in the lung (144).

There have also been investigations to determine whether the degree of viral load is correlated with respiratory disease (141, 146). In a study of 27 lung transplant recipients, CMV loads of >500,000 copies/ml of BAL fluid were highly correlated with biopsy-proven CMV pneumonia (141). The viral load in the BAL fluid was also correlated with the severity of CMV lung tissue involvement, as measured by histopathologic findings and IHC staining (73). CMV NAT of BAL fluid has been suggested as a better marker of CMV pneumonia in lung recipients than CMV NAT of the blood, since sporadic cases of “compartmentalized” pneumonia without concomitant viremia have been reported (147). While CMV NAT of BAL fluid has been correlated highly with CMV disease in the lungs by some (148), others have found no correlation (149). Such discrepant results may be due to a lack of standardization in various aspects of sample collection and testing, including the amount of fluid effluent, sampling error, and assay performance characteristics. In addition, differences in patient risk profiles may account for the discrepant findings.

(v) Urine and other specimens. CMV can also be detected in urine and stool, although these are generally not recommended as
other factors (Table 4) (6), there was up to a 3-log \(_{10}\) variation in viral loads reported among different CMV QNAT assays using common samples (97). In a multicenter study conducted across 33 laboratories in Europe and North America, variability in viral load results for individual samples ranged from 2.0 log \(_{10}\) copies/ml to 4.3 log \(_{10}\) copies/ml (97). For example, a clinical sample with 100 copies/ml of CMV reported by one assay may have shown 100,000 copies/ml when tested by another method (97). There was also significant intralaboratory variability, although at a lesser degree than that between laboratories (97). Likewise, another multisite assessment of CMV NATs in 23 laboratories (including 22 which used LDTs on a wide variety of platforms) showed significant interassay quantitative variability in viral load reporting (157). Ten of the laboratories reported viral load values that were significantly different from the expected values (with bias ranging from −0.82 to 1.4 log) (157). This study further determined that changes in reported viral loads of <3- to 5-fold for similar assays may not be significantly different (157). These studies indicated that standardization of NAT methodologies and the presence of a common CMV DNA reference standard are needed to allow laboratories to achieve comparable numeric results (97, 157).

Based on such findings, in November 2010, the WHO released the first international reference standard (NIBSC 09/162) for the quantification of CMV nucleic acid by NAT (7). This reference standard comprises a whole-virus preparation of the human CMV Merlin strain, formulated in a universal buffer comprising Tris-HCl and human serum albumin. This standard material was evaluated in a worldwide collaborative study of 32 laboratories performing NAT-based assay of CMV (7). When reconstituted in 1 ml of nuclease-free water, the material has been assigned a concentration of 5 × 10^6 international units (IU). The U.S. National Institute of Standards and Technology produced a standard reference material can be expected to address this issue. The interaction among any of the above variables may compound and increase the variability of viral load reporting.

### Table 4 Selected factors contributing to interassay variability in viral load reporting among quantitative nucleic acid amplification tests

<table>
<thead>
<tr>
<th>Major factor</th>
<th>Specific variable(s)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample selection and specimen volume</td>
<td>Blood compartments</td>
<td>Higher viral load obtained with whole blood and cell-containing compartments than with plasma or serum</td>
</tr>
<tr>
<td>Pipetting technique</td>
<td>Automated vs manual pipetting devices</td>
<td>Viral load reporting may depend on the efficiency of viral nucleic acid extraction; in one study, the lowest level of variability in viral load reporting was observed for those methods using liquid-phase extraction compared to magnetic bead and silica membrane extraction (see the text); the volume of sample for nucleic acid extraction may also affect viral load reporting</td>
</tr>
<tr>
<td>Nucleic acid extraction</td>
<td>Liquid-phase magnetic beads, silica membrane/column</td>
<td>Multiple studies have demonstrated differences in viral load reporting depending on the assay platform (see the text)</td>
</tr>
<tr>
<td>PCR instrument</td>
<td>TaqMan, LightCycler or iCycler, others</td>
<td>Differences in amplification efficiency have been demonstrated among various gene targets; the presence of gene polymorphisms in the gene target can reduce sensitivity and quantitative results (see the text)</td>
</tr>
<tr>
<td>Molecular amplification targets</td>
<td>CMV polymerase gene, glycoprotein B gene, immediate-early gene, others</td>
<td>One study identified detection reagents as the biggest contributor to overall assay variability</td>
</tr>
<tr>
<td>Probe chemistry</td>
<td>Hydrolysis (TaqMan), fluorescence resonance energy transfer (FRET)</td>
<td>One of the most significant variables associated with interassay variability; different quantitative standards can have dramatic effects on viral load results; the introduction of the first WHO international CMV reference standard and the U.S. National Institute of Standards and Technology standard reference material can be expected to address this issue</td>
</tr>
<tr>
<td>Detection reagents</td>
<td>Real-time EIA Southern blot</td>
<td>The interaction among any of the above variables may compound and increase the variability of viral load reporting</td>
</tr>
</tbody>
</table>
| Calibrators                      | Abbott, Acrometrix, Advanced Biotechnologies, Qiagen, Roche | kerning of 5 × 10^6 international units (IU). The U.S. National Institute of Standards and Technology also produced a standard reference material (SRM2566) for CMV that is appropriate for establishing metrological traceability of assay calibrants (158). Availability of these standards should allow common calibration of both commercially developed CMV NAT and LDTs. To date, the only commercial test that has been approved by the U.S. FDA for CMV disease monitoring is the COBAS AmpliPrep/COBAS TaqMan CMV test (CAP/CTM CMV Test; Roche Molecular Diagnostics), which has been calibrated based on the WHO standard and produces results in IU/ml (5). In a study that compared the performances of the CAP/CTM CMV test across five centers in the United States and Europe, there was a high level of quantitative agreement in the reported viral loads across different test centers (4). However, there was high quantitative variability observed for the CAP/CTM CMV test at lower viral load values, at or near the lower limit of detection (i.e., 2.8 log_{10} copies/ml) (4). With such low viral loads, the CAP/CTM CMV test detected all positive samples but was able to provide quantitative results for only 83% of samples (4). The most stable viral load results, with the lowest interlaboratory variability, were those within the middle range of the assay (4). Interestingly, the samples were also tested by the existing noncalibrated CMV NAT assays in the five laboratories, which showed high interassay quantitative variability (4). For three of the five assays (real-time PCR based on Artus reagents [Qiagen] and LDTs targeting UL111a and pp65 gene targets), reported values were higher than those from the CAP/CTM CMV test, while differences were variable across the quantitative testing range for the other two tests (Affigen real-time PCR test [Cepheid] and COBAS Amplicor Monitor CMV test [Roche]). This study again emphasized the high variability among assays that...
have not been calibrated to the WHO standard (4). Another study recently compared the performance of an LDT and the commercially available RealTime CMV assay (Abbott) in 513 samples obtained from 37 transplant patients (159). There was significant correlation between the two assays, but despite standardized reporting in international units, using the WHO reference standard, there were discordant results for 23% of samples (positive by the Abbott assay and negative by the LDT). These studies emphasize that even in the presence of an international reference standard, there are still potential differences in viral load test results, based on other variables, such as the assay’s performance characteristics and limits of detection (159).

Indeed, while the availability of the international reference materials may significantly harmonize viral load reporting (i.e., in IU/ml) (4), there remains assay-specific variability due to other differences in test characteristics. Differences in nucleic acid extraction methods, type and volume of clinical samples, selection of primers and probes, target-specific amplification efficiencies, detection chemistries and reagents, instrumentation, and operator-dependent variability may independently or collectively account for assay-specific variability (Table 4) (6). One study reported that differences in nucleic acid extraction efficiency over a wide range of plasma CMV DNA loads could account for differences in viral load reporting (160). Another study showed that among three methods of nucleic acid extraction used for CMV NAT, the lowest variability was observed for liquid-phase compared to silica membrane/column and magnetic bead methods (6).

Differences in viral load reporting may be observed if the assay is run on different platforms (such as Abbott, Roche LightCycler, and Nanogen PCR platforms) (160). There are also various amplification efficiencies based on the primers used (161). For example, in a study that compared three different primer sets (UL125 alone, UL126 alone, and UL55/UL123-exon 4), the double-primer assay demonstrated the highest sensitivity, specificity, and predictive values (99). In a large study of laboratory proficiency testing, amplification of the CMV DNA polymerase gene yielded lower mean viral loads than those obtained using glycoprotein B, immediate-early, major immediate-early, and other genes (6). One factor that could partly account for the various efficiencies observed is the presence of genetic mutations or polymorphisms in the chosen gene target. The presence of genetic polymorphisms or mutations in target genes can impede primer binding, reduce PCR efficiency, and reduce sensitivity. Interactions among several apparently independent assay designs and characteristics have also been observed to increase the variability in viral load reporting (6). Thus, standardization of quantitative calibrators, while a great step forward, will not completely eliminate variability of results. Other issues will need to be addressed over time to ensure uniformity in CMV load reporting. The availability of automated commercial PCR tests that encompass all aspects of specimen preparation and testing may be another significant step in this direction (6).

In addition, preanalytical considerations may affect the performance of these tests (Table 4). These include specimen selection and volume, collection, and transport. Storage conditions of clinical samples for PCR testing may affect viral load results, and while one study suggested that storage should not last longer than 72 h (162), another showed stability for up to 14 days (114). As noted earlier in this review, the type of clinical sample may play a role, with whole-blood samples yielding higher values (about a 1-log10 difference) than those obtained with plasma samples (126, 128).

Several other test characteristics are important to consider, including the upper and lower limits of detection and quantification (i.e., the highest and lowest concentrations of DNA that can be detected and quantified in 95% of replicates, respectively), linear range, precision, and accuracy. Finally, variations in patient populations being studied and their level of immunosuppression may account for viral load variability, and thus, viral load threshold recommendations may need to be specific for every type of organ transplant, risk stratum, and level of immunosuppression (3).

**Non-PCR amplification methods.** There are several non-PCR methodologies for CMV diagnosis based on signal amplification methods rather than on direct detection of CMV DNA or RNA by target amplification methods such as PCR (Table 3). Examples of signal amplification methods include the branched DNA (bDNA) assay (Chiron Corporation, Emeryville, CA) and the hybrid capture assay (HCA; Qiagen, Hilden, Germany [previously Digene Diagnostics]). The bDNA signal amplification assay measures viral nucleic acid from clinical specimens by using bDNA amplifiers to boost the reporter signal rather than amplifying the target sequences. The target nucleic acid binds to the bDNA molecule, which contains multiple binding sites for an enzyme labeled probe, and the target-bDNA complex is detected with a chemoluminescent substrate. The intensity of the light output is directly proportional to the amount of DNA in the clinical sample. Because it does not amplify the signal, it has been considered to be less sensitive than PCR-based assays (163).

The HCA is a solution hybridization antibody capture assay that uses a cRNA probe to hybridize with the CMV DNA target (reported to be 17% of the CMV genome) (141, 164–166). The target-probe complex (termed a DNA-RNA hybrid) is captured by antibodies specific to the hybrid, and the resulting signal (chemiluminescence) is then measured by a luminometer. The amount of light emitted is quantified and is proportional to the amount of DNA in the clinical sample. The clinical application of HCA has been demonstrated in several studies conducted on SOT recipients (141, 167–169), and these studies suggested the correlation between high viral load and the risk of CMV disease. Few studies have reported lower sensitivities than those of antigenemia and PCR-based assays (165, 170).

Another methodology that has been used for CMV diagnosis in SOT recipients is nucleic acid sequence-based amplification (NASBA), which is a specific isothermal technique of amplification (163). One example of a specific test that has been developed based on NASBA technology is the Nuclisens pp67 test (Organon Teknika), which monitors CMV late pp67 mRNA expression. The Nuclisens pp67 assay has been tested in a few studies of SOT recipients (171), although its clinical use is not as widespread as that of PCR-based assays. In a study that assessed its performance in comparison with antigenemia and PCR-based testing, the Nuclisens pp67 test had the lowest sensitivity (20% versus 65% and 95%, respectively) (94). However, it has the highest specificity for CMV disease (93%). The pp67 mRNA assay was highly effective in identifying those with very high CMV loads (94). However, in another study, the pp67 mRNA test was not able to detect the virus in 4 of 11 patients who developed CMV disease (163). Its low to modest sensitivity has limited its use and application in clinical practice. Development of a more sensitive assay, and preferably one with quantitative capability, is needed (172).
TABLE 5 Clinical utility of viral load in solid organ transplant recipients

<table>
<thead>
<tr>
<th>General indication of use</th>
<th>Specific clinical utility</th>
<th>Comments*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prognostication</td>
<td>Assessment of CMV disease risk</td>
<td>Higher initial and peak viral loads are associated with a higher risk of CMV disease development (see the text); a rapid rise or upward trend in viral load is associated with a higher risk of CMV disease development (see the text)</td>
</tr>
<tr>
<td></td>
<td>Assessment of CMV disease severity</td>
<td>Higher viral loads are associated with more severe CMV disease, tissue-invasive CMV disease, and potential multiorgan involvement (see the text)</td>
</tr>
<tr>
<td>Prevention</td>
<td>Guidance in the initiation and duration of preemptive therapy</td>
<td>Detection of a viral load above a predefined assay-specific threshold is an indication for the initiation of preemptive antiviral therapy; weekly NAT will guide in determining duration of preemptive therapy (see treatment below)</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Rapid and sensitive diagnosis of CMV infection</td>
<td>Rapid and sensitive detection of CMV in the blood or tissue of patients with compatible clinical symptoms confirms the clinical suspicion of CMV disease; higher viral loads are associated with more severe CMV disease, tissue-invasive CMV disease, and potential multiorgan involvement; a negative CMV NAT in blood does not completely rule out CMV disease if the clinical suspicion is high—in this case, pursue other diagnostic tests</td>
</tr>
<tr>
<td>Treatment</td>
<td>Assessment of efficacy of antiviral therapy</td>
<td>Weekly NAT will indicate the decline in viral load as a measure of the efficacy of antiviral therapy</td>
</tr>
<tr>
<td></td>
<td>Assessment of treatment duration</td>
<td>Higher pretreatment viral loads (e.g., &gt;18,200 [4.3 ( \log_{10} ) IU/ml] have lower rates of CMV disease resolution; viral load suppression (e.g., &lt;137 IU/ml or &lt;2.1 ( \log_{10} ) IU/ml) is associated with a shorter time to clinical CMV disease resolution</td>
</tr>
<tr>
<td></td>
<td>Assessment of risk of relapse</td>
<td>Detection of a viral load above a threshold at the end of antiviral treatment is significantly associated with clinical and virological relapse; viral decay ( (t_{1/2}) ) in patients with successful antiviral treatment was 3.17 days, compared to 8.8 days for patients with subsequent CMV relapse</td>
</tr>
<tr>
<td></td>
<td>Assessment of risk of antiviral resistance</td>
<td>Persistent detection (or rise) of viral load in a patient receiving a prolonged course of antiviral therapy is a surrogate for the presence of a drug-resistant virus</td>
</tr>
</tbody>
</table>

* The viral load thresholds for most clinical indications have not been defined due to the lack of a standardized assay in most studies that have reported these clinical uses. See the text for examples of viral load thresholds specific to assays used and populations studied.

CLINICAL CORRELATION

CMV NAT has revolutionized the contemporary management of CMV disease in SOT recipients. Not only does CMV NAT allow for the rapid diagnosis of CMV infection, but its quantitative capabilities have introduced several principles that are relevant to CMV prevention and treatment, including risk stratification, early detection for preemptive therapy, assessment of antiviral treatment responses, and assessment of disease relapse (Table 5). Multiple studies conducted over the past 2 decades have highlighted these clinical indications for CMV load testing. However, due to the lack of standardization until recently, there have been no widely accepted viral load thresholds that can be applied universally for these various clinical indications across centers. With the attempt to standardize reporting, there are now emerging data to suggest such viral thresholds, as discussed below.

Risk Stratification

From the sites of initial reactivation, CMV disseminates in the blood and may spread to other organs. There is strong evidence that the degree of CMV dissemination in the blood, as measured directly by absolute CMV load values, is a significant risk factor for progression from CMV infection to symptomatic disease (173). The initial viral load has been correlated significantly with peak CMV load and with CMV disease in liver (odds ratio [OR], 1.82 [95% CI, 1.11 to 2.98]; \( P = 0.02 \)) and kidney (OR, 1.34 [1.07 to 1.68]; \( P = 0.01 \)) transplant recipients (43). In a study of liver transplant recipients, the risk of CMV disease was 8.8-fold and 51.5-fold higher among those with a detectable CMV load but <2,860 copies/10⁶ PBL and those with >2,860 copies/10⁶ PBL, respectively, than among those with an undetectable viral load (127). Several other studies have confirmed these observations by demonstrating that transplant recipients predisposed to develop CMV disease have significantly higher viral loads than those in patients without symptoms (151, 167, 173–177). These observations collectively serve as the basis for the use of CMV NAT in the blood as a prognostic marker of risk for CMV disease.

However, the numerical viral load values that reliably predict CMV disease risk compared to asymptomatic infection have not been defined, and they vary among various tests (due to a lack of assay standardization). Moreover, the viral load values are likely influenced by a patient’s underlying level of immunity. Higher viral loads are expected in CMV D+R− SOT patients with CMV disease than in CMV-seropositive patients, even using the same assay (Table 1) (178). Lung transplant recipients, who are likely more immunosuppressed, are likely to have higher viral loads than those of liver or kidney transplant recipients. Although there is considerable overlap, the viral load is generally higher in patients with tissue-invasive and disseminated disease than in those with CMV syndrome (155, 178). In a recent study using a CMV test that has been calibrated to the WHO international standard, the mean baseline viral load of patients with CMV syndrome was 9,120 (3.96 \( \log_{10} \) IU/ml), compared to 20,893 (4.32 \( \log_{10} \) IU/ml) in patients with tissue-invasive CMV disease (5). A contribution of viral genotype to the level of viral load has also been suggested, although recent studies indicate that this may not be the case (179, 180).

In addition to absolute viral load values (i.e., initial and peak viral loads), trends (or changes over time) in viral load have also been used for CMV disease risk stratification (36, 41–43, 178). The risk of CMV disease is significantly higher in SOT recipients, with a faster and steeper rise in viral load over time (36, 41–43, 178). In one study, the rate of increase in CMV load between the last PCR-
negative and first PCR-positive sample was significantly higher in patients who developed CMV disease than in those who did not (0.33 log10 versus 0.19 log10 genomes/ml daily; \( P \leq 0.001 \)). In multivariate regression analyses, the rate of viral load increase was an independent risk factor for CMV disease (OR, 1.52 [1.06 to 2.17] \( P = 0.02 \), per 0.1-log10 increase in CMV load/ml daily) (43). However, the exact log change in viral load that is clinically relevant based on CMV biology in SOT recipients has yet to be defined. While a 1-log change is considered significant for most viral infections, the significant change in value may be higher for CMV, especially at lower viral load levels (4, 159). One study recently suggested that a change in viral load of <3- to 5-fold might not be significantly different (157).

**Preemptive Therapy**

Preemptive therapy is one of the two major strategies for preventing CMV disease in SOT recipients (Table 6) (3). In contrast to the strategy of antiviral prophylaxis (34, 38), wherein all at-risk SOT patients receive antiviral drugs, most commonly valganciclovir, for a defined period after transplantation, preemptive therapy provides antiviral drugs only to those with evidence of asymptomatic CMV infection, as detected by CMV NAT (Fig. 1) (3).

### TABLE 6 Prevention of CMV disease in solid organ transplant recipients

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Preemptive therapy</th>
<th>Antiviral prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Strategy</strong></td>
<td>Monitor patients for CMV reactivation by using highly sensitive and predictive laboratory assays (such as nucleic acid amplification tests)</td>
<td>Administer antiviral drug (valganciclovir) for a defined duration to all patients at risk for CMV disease (duration varies depending on the organ transplant and the risk profile of patients)</td>
</tr>
<tr>
<td>Laboratory monitoring is performed once weekly. More frequent monitoring may be considered for patients at very high risk of CMV disease</td>
<td>Laboratory monitoring (NAT) for CMV reactivation is not routinely recommended for patients receiving antiviral prophylaxis</td>
<td></td>
</tr>
<tr>
<td>Administer antiviral therapy (valganciclovir) only to patients who develop CMV reactivation above a predefined viral load threshold</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monitor patients by use of CMV NAT once weekly to guide treatment duration; treatment is continued until the viral load falls to an undetectable level or below a predefined threshold</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Recommended populations</strong></td>
<td>CMV-seropositive (CMV D+/R+ and CMV D−/R+) heart, liver, kidney, and pancreas transplant recipients</td>
<td>All CMV D+/R− solid organ transplant recipients</td>
</tr>
<tr>
<td>Considered but less preferred for CMV D+/R− heart, liver, kidney, and pancreas transplant recipients due to potential risk of breakthrough disease as a result of rapid replication dynamics</td>
<td>All CMV D+/R− and CMV R+ lung, intestinal, and composite tissue allograft transplant recipients</td>
<td></td>
</tr>
<tr>
<td>Not recommended for lung, intestinal, and composite tissue allograft transplant recipients</td>
<td>All CMV-seropositive (CMV D+/R+ and CMV D−/ R+) heart, liver, kidney, and pancreas transplant recipients</td>
<td></td>
</tr>
<tr>
<td>Considered but less preferred for CMV D+/R− patients between scheduled weekly testing</td>
<td>All transplant patients in centers that do not have an available assay for sensitive detection of CMV reactivation</td>
<td></td>
</tr>
<tr>
<td>Not recommended for lung, intestinal, and composite tissue allograft transplant recipients</td>
<td>All CMV-seropositive (CMV D+/R+ and CMV D−/R+) heart, liver, kidney, and pancreas transplant recipients</td>
<td></td>
</tr>
<tr>
<td><strong>Advantages</strong></td>
<td>Reduced no. of patients exposed to antiviral drugs</td>
<td>Prevents reactivation of other herpesviruses (i.e., herpes simplex virus, HHV-6)</td>
</tr>
<tr>
<td>Reduced direct antiviral drug costs</td>
<td>Does not rely on a highly sensitive and predictive assay for CMV detection</td>
<td></td>
</tr>
<tr>
<td>Reduced duration of antiviral drug use</td>
<td>Reduces incidence of indirect CMV effects</td>
<td></td>
</tr>
<tr>
<td>Reduced toxicity related to antiviral drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lower risk of antiviral drug resistance</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Disadvantages</strong></td>
<td>Requires a predictive test for early identification of patients at risk of CMV disease</td>
<td>Prolonged antiviral drug use may lead to emergence of antiviral drug resistance</td>
</tr>
<tr>
<td>Requires patients to comply with stringent laboratory surveillance schedule</td>
<td>Prolonged antiviral drug use may lead to higher incidence of adverse drug effects</td>
<td></td>
</tr>
<tr>
<td>No widely accepted viral load threshold for initiation of antiviral therapy</td>
<td>Use of expensive drugs by all patients, including those who may not have viral reactivation</td>
<td></td>
</tr>
<tr>
<td>Increased cost of diagnostic surveillance testing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>May not identify all patients at risk of CMV disease (breakthrough infection may occur in high-risk CMV D+/R− patients between scheduled weekly testing)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CMV-selective nature does not prevent reactivation of other herpesviruses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prolonged duration of preemptive antiviral therapy may be associated with drug resistance</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\( ^{a} \) CMV, cytomegalovirus; HHV, human herpesvirus.
This strategy of preemptive therapy takes advantage of one of the hallmarks of CMV disease pathogenesis, i.e., viral dissemination in the blood. Detection of CMV reactivation early in its course, as it starts to disseminate in the blood, is therefore a prerequisite for successful preemptive therapy (3, 181). Use of a rapid and sensitive diagnostic test such as NAT has enabled clinicians to detect CMV replication early in its course and prior to the onset of clinical disease (3, 124, 178).

With this preemptive therapy approach, SOT recipients undergo serial CMV surveillance during the period at highest risk of CMV reactivation (Fig. 1) (3, 166). The traditional at-risk period is the first 3 months after SOT; hence, guidelines recommend performance of weekly CMV surveillance for 12 weeks after transplantation. In the current era, preemptive therapy has also been applied as part of a hybrid approach to prevent late-onset CMV disease (182, 183). In this regard, high-risk CMV D+/R− SOT recipients who receive antiviral prophylaxis as a primary strategy for CMV prevention undergo CMV surveillance by NAT after completion of CMV prophylaxis (182, 183). At least two studies have assessed the efficacy of this approach (182, 183). One study evaluated the approach of performing CMV NAT every 2 weeks for 3 months after completion of prophylaxis, while another performed CMV NAT once weekly for 8 weeks after completion of antiviral prophylaxis. In both studies, the clinical utility of this hybrid approach was considered modest, since breakthrough CMV disease may still occur (if the patient is tested less frequently) (182), and CMV disease may still occur beyond the period of active CMV surveillance (if the period of surveillance is not long enough) (183).

Once-weekly CMV surveillance is the recommended frequency of laboratory testing for preemptive therapy. The majority of published studies on preemptive therapy have performed once-weekly CMV surveillance during the first 3 months after SOT (3, 124, 127). Some centers have performed CMV surveillance every 2 weeks (102, 103, 184), while others have observed that even once-weekly testing may not be frequent enough for high-risk groups (and hence they recommend twice-weekly monitoring) (124, 127, 178). In a cohort of liver transplant recipients undergoing once-weekly NAT surveillance for preemptive therapy, a significant number of CMV D+/R− patients developed clinical symptoms during the period between once-weekly testing, or at the time of first PCR positivity (124, 127). The failure to detect CMV early in its course was likely due to the rapid CMV replication dynamics in CMV D+/R− SOT recipients (36). Hence, the frequency of CMV testing may be tailored according to the underlying risk profile, with more frequent testing recommended for the high-risk CMV D+/R− group. In one study, the rate of increase in viral load in whole blood was significantly higher for CMV D+/R− patients, with a median doubling time of 1.54 days (range, 0.5 to 5.5 days), compared to 2.67 days (range, 0.27 to 26.7 days) for the CMV D+/R+ group (178). Because of the rapid CMV replication dynamics in CMV D+/R− SOT recipients, antiviral prophylaxis has been recommended for these patients, especially when frequent CMV surveillance is not logistically possible (Table 6) (3). Alternatively, others have recommended and performed more frequent CMV monitoring (i.e., twice weekly) for this high-risk group (178).

Upon CMV detection above a predefined center-specific viral...
load threshold, antiviral therapy (usually oral valganciclovir and, less commonly, intravenous ganciclovir) is initiated preemptively to prevent the progression of asymptomatic CMV infection into clinical disease (3, 185, 186). In one study, this approach reduced the incidence of CMV disease from 12% to 0% in a cohort of liver transplant recipients (124). What is still undefined is a widely accepted viral load threshold that can be applied universally (across different institutions) for preemptive therapy. It is therefore emphasized that previously reported thresholds should be interpreted with caution, depending on the assay used, specimen tested, and population studied (3). One center suggested a viral load of 1,000 to 5,000 copies/ml of plasma as the optimal threshold for guiding preemptive therapy in SOT recipients. Another center validated a viral load threshold of 3,000 genomes/ml of whole blood as the level that should trigger preemptive therapy, with the aim of preventing viral replication above 37,000 genomes/ml—a level associated with tissue-invasive CMV disease (178). Using CMV NAT to monitor 689 liver and kidney transplant recipients, CMV infection was demonstrated in 43% of recipients during the first 90 days after transplantation, but only 21% of patients reached viral loads above 3,000 genomes/ml. The majority of the patients who developed viremia that required antiviral therapy belonged to the high-risk CMV D+/R- group (viremia in this group developed in 78% of cases, and antiviral therapy was required in 69% of cases) (178). This was followed by the D+/R+ group (54% developed viremia, and 23% required antiviral therapy), while the D-/R+ group had the lowest rates (40% and 13%, respectively) (178). Based on these observations, the clinical utility of preemptive therapy may relate to the specific population being treated. Another center developed risk-specific viral load thresholds for preemptive therapy. In its report, viral load thresholds (as measured using a TaqMan assay [ABI Prism 7700 sequence detection system]) of 1,000 copies, 4,000 copies, and 10,000 copies/ml of whole blood were suggested as indicators for initiating preemptive antiviral therapy in high-risk, moderate-risk, and low-risk transplant groups, respectively (89). A more recent prospective study that quantified viral load by using standardized CMV NAT suggested 3,983 IU/ml of plasma as the threshold for initiation of preemptive therapy in moderate-risk, CMV-seropositive liver, kidney, and heart transplant recipients (187). That cutoff value, which was first defined in a study of 141 CMV-seropositive SOT recipients (derivation cohort) and validated in a prospective study of 252 transplant recipients (validation cohort), had an 89.9% sensitivity and 88.9% specificity in correctly identifying the need for preemptive therapy, with a negative predictive value of 99.6% (187). Similar studies must be performed to confirm this finding and to derive and validate viral load thresholds for preemptive therapy in high-risk CMV D+/R- SOT recipients and other transplant populations.

Overall, the use of preemptive antiviral therapy, as guided by CMV NAT, in patients with asymptomatic CMV infection has resulted in a significant reduction in the incidence of CMV disease in SOT recipients (181). Individual clinical trials and collective data from meta-analyses have clearly shown the benefits of NAT-guided preemptive therapy for CMV disease prevention (124, 188). Based on these studies, NAT-directed preemptive therapy is recommended as a strategy for CMV disease prevention in CMV-seropositive heart, liver, kidney, and pancreas transplant recipients (3). While this approach has also been demonstrated to be effective with CMV D+/R- SOT recipients, the current guidelines recommend antiviral prophylaxis for this high-risk patient group, if frequent CMV surveillance is not logistically feasible, due to the high rate of viral replication in these patients (3). Likewise, lung, intestinal, and composite tissue allograft transplant recipients should receive antiviral prophylaxis rather than preemptive therapy, because of the high risk of CMV disease in these patient groups (3) (Table 6).

Rapid Diagnosis

The earliest clinical use of CMV NAT was for the rapid and sensitive diagnosis of CMV disease in SOT recipients (2). Clinicians use NAT to assess the likelihood that a patient with compatible clinical symptoms has active CMV disease. During most CMV infections, there is hematogenous viral dissemination which can be captured by peripheral blood NAT. Quantitative results from such testing (viral loads) have been used as an objective measure of CMV disease activity and severity.

The clinical diagnosis of CMV syndrome in SOT patients with fever, arthralgias, myalgias, and bone marrow suppression is confirmed if CMV DNA is demonstrated in the blood. The diagnosis is generally confirmed if the CMV load is high and no other pathogens can be demonstrated. In a study of kidney transplant recipients who developed late-onset CMV disease, the median peak viral load in symptomatic patients was 13,500 copies/ml and ranged from as low as 400 copies/ml (lowest limit of detection for the assay) to as high as 2,831,000 copies/ml (189). The wide variability in the viral loads reported in this study illustrates the difficulty in defining the clinically relevant value. The viral load value is likely influenced by the patient’s immune status and the clinical stage of the infection disease. For example, viral load values are higher for patients with CMV disease than for those with asymptomatic infection (190) and for those with severe disease than for those with milder infections (138). On the other hand, a negative CMV NAT result for a febrile patient is a strong argument against CMV syndrome, and clinicians should search for alternative diagnoses (with few exceptions, as noted below) (191, 192).

The clinical diagnosis of tissue-invasive CMV disease is also supported by the demonstration of a high peripheral blood CMV load (3, 189, 190). Ideally, CMV should be demonstrated at the site of tissue invasion, such as BAL fluid for CMV pneumonia, CSF for CMV encephalitis and meningitis, and vitreous humor for CMV retinitis, among others (3, 138). The degree of viral load in these clinical specimens, including BAL fluid and CSF, has been associated directly with the severity of infection (73, 138, 141). However, clinicians are hesitant to perform such invasive biopsy procedures on immunocompromised and often critically ill patients. Hence, in patients with compatible signs and symptoms of tissue dysfunction, the clinical suspicion of tissue-invasive CMV disease can be supported by peripheral blood CMV NAT (3). Such testing sometimes obviates the need for histopathologic diagnosis of tissue-invasive CMV disease (54). In clinical practice, the diagnosis of gastrointestinal tissue-invasive CMV disease may be suggested by a high-copy-number blood viral load in a patient with diarrhea and other symptoms (54). Likewise, the diagnosis of CMV pneumonitis may be suggested for a patient with pulmonary symptoms, radiographic findings, and a high viral load in the peripheral blood (141). High viral loads are often seen in patients with multiorgan tissue-invasive disease, and lower values may be seen in those with localized or compartmentalized CMV disease. A response to antiviral therapy, as indicated by a decline in viral load, is a strong indicator that antiviral therapy is effective.
load and resolution of clinical symptoms, further supports the diagnosis of tissue-invasive disease. Unresponsiveness to antiviral therapy, as evidenced by a nondeclining or rising viral load, may warrant a further investigation for alternative etiologic agents or raise the possibility of antiviral resistance (3, 74).

Peripheral blood CMV NAT may be negative for a proportion of patients with CMV disease (3, 5). In a cohort of 267 patients with CMV disease, 11.7% had no quantifiable viral load (i.e., loads were lower than the assay reporting value of 137 [2.14 log10 IU/ml]) (5). There are several possible reasons for a negative CMV NAT result in the presence of CMV disease. The infection may be a form of compartmentalized tissue-invasive disease, wherein the infection is localized in an organ with no systemic dissemination. A number of CMV-seropositive SOT patients with gastrointestinal CMV disease have no detectable CMV viremia (193). These patients often present late, generally many years after transplantation (193). Diagnosis in these cases is generally confirmed by tissue biopsy and histology with ISH (193). Rare cases of CMV retinitis in SOT recipients, especially those that occur late, also generally present without concomitant viremia (139). Diagnosis of CMV retinitis is generally confirmed by detailed funduscopic examination and demonstration of CMV in vitreous fluid by NAT (139). CMV NAT may also give a falsely negative result if the viral load is below the limit of assay detection for the assay being used. Peripheral blood CMV NAT may be negative if sampling occurs prior to the onset of viremia or after viremia has subsided, as in cases of delayed diagnosis, although this is rare. Finally, CMV NAT may be negative (or yield a falsely low viral load) if the virus has genetic polymorphisms in the PCR target gene, reducing the efficiency of viral amplification (6). To confirm the clinical suspicion of tissue-invasive CMV disease in these nonviremic situations, one may repeat the NAT at a later time point, use another NAT assay with higher sensitivity or a different genetic target, or obtain tissue for histopathologic diagnosis (34). In such cases, one should strongly consider sampling body fluid or tissue from the suspected site of infection, such as the aqueous and vitreous humor fluid for patients suspected to have CMV retinitis (139, 194), BAL fluid for patients suspected to have CMV pneumonia (142, 143), and CSF for patients suspected to have CMV encephalitis, meningitis, or polyradiculopathy (147, 195, 196).

Treatment Response

CMV load may be used to assess the response to antiviral treatment and to determine antiviral treatment endpoints. In this regard, three different measures have been proposed: (i) initial viral load at diagnosis, (ii) viral load decline, and (iii) viral load suppression. These three principles apply to antiviral treatment of established CMV disease and to preemptive treatment of asymptomatic CMV infection.

Viral load at time of diagnosis. Viral load at the time of diagnosis has been correlated with antiviral treatment efficacy (197). In a large clinical trial that compared oral valganciclovir and intravenous ganciclovir for the treatment of CMV disease in 321 SOT recipients, baseline (pretreatment) viral load was the only predictor that was significantly associated with viral load eradication at the end of treatment (197). SOT recipients with viral loads of <10,000 copies/ml had a 6.4-fold higher chance of eradicating the virus after 21 days of induction treatment and a 2.5-fold higher chance of eradicating the virus at day 49 of treatment than those with viral loads of >10,000 copies/ml of plasma (197). In general, a higher viral load at diagnosis has been associated with a longer course of treatment and a higher risk of treatment relapse. In another study of kidney and liver transplant recipients, the total duration of antiviral treatment was associated with peak viral load at the start of treatment (178). Each 1-log-higher peak viral load was associated with a 31-day longer (95% CI, 19 to 43 days) total treatment time (178). In a more recent study of 267 SOT recipients who received intravenous ganciclovir and valganciclovir for treatment of CMV disease, CMV disease resolution was again correlated with pretreatment viral load. Using an assay that has been calibrated to the WHO international standard, SOT recipients with a pretreatment CMV load of <18,200 (4.3 log10 IU/ml) had a shorter time to clinical CMV disease resolution than those with a higher CMV load (adjusted hazard ratio [AHR], 1.56; P = 0.001) (5). The median time to clinical resolution was 5 days longer for those with a higher viral load (12 days versus 7 days) (5).

Viral load decline. Viral load decline over time has been suggested as a measure of therapeutic efficacy. Thus, SOT patients should undergo CMV surveillance during antiviral treatment (197). In a study of patients with asymptomatic CMV infection, the viral decay (also known as half-life) for 22 patients receiving preemptive valganciclovir treatment was 2.16 days, which was comparable to the viral decay of 1.73 days for 23 patients who received preemptive intravenous ganciclovir (198). In another study of patients with CMV disease and subclinical CMV viremia, the median half-life was 4.78 days in plasma, 5.78 days in whole blood, 4.42 days in peripheral blood mononuclear cells, and 5.10 days in peripheral blood leukocytes during treatment with intravenous ganciclovir (126). During treatment of established CMV disease, one study demonstrated a viral half-life of 5 to 8 days (44). In a large cohort of SOT patients with established CMV disease, the viral load half-life was 11.5 days (range, 8.3 to 16.5 days) for patients receiving oral valganciclovir treatment and 10.4 days (range, 7.9 to 14.5 days) for patients receiving intravenous ganciclovir (197). Based on these studies, once-weekly CMV monitoring is recommended to assess therapeutic responses (3). Assessing the viral load response sooner (before 7 days) or more frequently is generally not recommended, since there is often a lag time before the reduction in viral load is observed (197). The mean time to clinically relevant viral load decline was 6.1 ± 4.5 days for patients treated with oral valganciclovir and 6.6 ± 4.7 days for those treated with intravenous ganciclovir (197).

A decline in the peripheral blood viral load generally indicates that a patient is responding appropriately to antiviral treatment (80, 197, 199). In a study of 19 episodes of CMV disease, the viral load declined from the pretreatment mean value of 45,412 to 8,721 copies/ml of whole blood after 1 week of intravenous ganciclovir treatment (126). A similar pattern of viral decline was observed in plasma, peripheral blood mononuclear cells, and peripheral blood leukocytes (126). However, a recent study that utilized the WHO international standard for viral load reporting did not find a significant association between relative CMV load reductions from baseline of predefined magnitudes (1.0-, 1.5-, 2.0-, and 2.5-log declines) and faster disease resolution (5). It is possible that the association between clinical response and the degree of viral load decline is complex, and it may vary depending on the severity of clinical disease, degree of initial viremia, degree of peak viremia, and underlying level of immunosuppression.

The majority of SOT recipients demonstrate a decline in viral load during the first week of antiviral treatment. However, in
some cases, the viral load may rise during the first few days to up to 2 weeks of antiviral treatment (200). This intermittent rise or fluctuations in some patients are often benign and will be followed eventually by a satisfactory decline in viral load over ensuing weeks (this pattern has also been observed with antigenemia testing). While this may be a natural course in these patients, the rise in viral load should raise the potential for treatment failure, recurrent disease, or drug-resistant CMV disease.

Viral load suppression. Antiviral treatment is generally continued until clinical resolution is achieved and viral eradication is demonstrated. Clinical response appears earlier than viral clearance. In a clinical trial that assessed antiviral treatment of CMV disease, the mean time to clinical resolution of symptoms was 15 days of antiviral treatment (range, 13 to 17 days) (197). However, viral eradication (<600 copies/ml) at treatment day 21 was achieved in only 45% of patients receiving valganciclovir and 48% of those treated with intravenous ganciclovir (197). In a recent study of 267 SOT recipients who received intravenous ganciclovir and valganciclovir for treatment of CMV disease, those with CMV load suppression (<137 IU/ml or <2.1 log_{10} IU/ml), as measured by a CMV NAT calibrated to the WHO international reference standard, at days 7, 14, and 21 had shorter times to clinical disease resolution than those without viral suppression, even after adjusting for potential confounders (AHR = 1.61, 1.73, and 1.64, respectively [P values of 0.005, <0.001, and <0.001, respectively]) (5). This finding translates to 5 days, 5 days, and 7 days longer for clinical disease resolution among patients with detectable virus at 7, 14, and 21 days of antiviral treatment (5). This recent report supports the current treatment guidelines recommending viral eradication from blood prior to discontinuing antiviral therapy. The duration of antiviral therapy may vary depending on the sensitivity of the NAT assay used for monitoring. Use of a highly sensitive PCR test for monitoring response may result in a longer course of treatment, while those monitored by less sensitive assays may be treated for shorter periods. Standardization of CMV NAT assays for monitoring is therefore needed, and viral values considered safe for cessation of antiviral therapy must still be defined. In one study, the risk of CMV disease relapse was not significantly different between patients with discordant positive whole-blood and negative plasma PCRs and those with negative whole-blood and negative plasma PCRs. This observation suggests that the higher sensitivity of whole-blood PCR assays may not be highly clinically relevant for assessing treatment responses (128). In these situations, antiviral therapy should be continued until the viral load is suppressed to levels below what is yet to be defined as a “safe threshold” for treatment cessation.

The total duration of antiviral treatment may also be influenced by the underlying immunologic risk profile of patients. The duration of viremia (and consequently the number of days needed for treatment) is generally longer for CMV D+/R− liver transplant patients (32 days; range, 7 to 87 days) than for D+/R+ (14 days; range, 1 to 111 days) and D−/R+ (5.5 days; range, 1 to 53 days) patients (178). A similar pattern was observed in kidney transplant recipients (178). Consequently, antiviral treatment is continued longer for D+/R− patients (43 days; range, 18 to 102 days) than for D+/R+ (25 days; range, 6 to 141 days) and D−/R+ (23 days; range not provided) liver transplant patients (178).

Relapse and Resistance

Viral load is used clinically as an objective measure of CMV disease activity (37). Hence, it is generally recommended that antiviral treatment be continued until the viral load is no longer detectable in the blood or has declined to a predefined threshold where it is safe to discontinue antiviral treatment (37). These recommendations are based on studies that have significantly associated relapse with the presence of detectable virus in the blood (37). These are further supported by a recent study, using an assay that has been calibrated to the WHO international reference standard, showing that viral load suppression to levels below 137 (2.14 log_{10}) IU/ml at the end of treatment is significantly associated with CMV disease resolution (5).

In a study of 24 SOT recipients with CMV disease, eight patients developed relapsing CMV infection following a 14-day course of intravenous ganciclovir treatment. Relapsing CMV infection was characterized by a significantly higher pretreatment (or baseline) viral load and the persistence of viral load in the blood at the end of treatment (45). In another study, recurrent CMV disease was observed in 12 (23%) of 50 SOT patients with CMV disease. The two factors that were associated with recurrent disease were (i) a longer time to viral clearance and (ii) a lack of viral eradication at the end of treatment (44). The viral load half-life was 8.8 days among patients with CMV recurrence, compared to only 3.17 days among patients who resolved their CMV disease without recurrence (44). In a recent study of 321 SOT recipients with CMV disease who received 21 days of intravenous ganciclovir or oral valganciclovir followed by valganciclovir maintenance for 4 weeks, recurrence of clinical disease was observed in 15.1% of patients, and virological recurrence was seen in 30.0% of patients. The only independent predictor of clinical and virological recurrence was a failure to eradicate viremia at day 21 (for clinical recurrence, the OR was 3.9 [1.3 to 11.3] [P = 0.012]; and for virological recurrence, the OR was 5.6 [2.5 to 12.6] [P < 0.0001]) (37). The vast majority of recurrent CMV infection and disease are due to ganciclovir-susceptible viruses, and these viruses should remain susceptible and respond well to retreatment with oral valganciclovir or intravenous ganciclovir (3, 201, 202). In a few cases, recurrence of CMV infection heralds the onset of disease due to drug-resistant virus (3, 201, 202).

To reduce the risk of CMV disease recurrence, some experts have recommended the use of secondary antiviral prophylaxis, wherein valganciclovir is given at prophylaxis doses following completion of induction antiviral therapy (3). However, the clinical utility of this approach is much debated. Several studies have demonstrated that this does not affect the rates of clinical and virological recurrence. In a study of gastrointestinal CMV disease treatment, the rates of recurrence did not differ significantly between those who received and those who did not receive secondary prophylaxis (54). Nonetheless, current guidelines do recommend such an approach for transplant patients who are considered at high risk of recurrence. For example, those patients with severe gastrointestinal involvement at the time of CMV disease diagnosis are at higher risk of relapse (54). Higher viral loads at diagnosis and peak viral load measures have also been associated with the risk of recurrence, albeit inconsistently (45, 54). However, there are currently no solid data to support the use of viral load measures to guide the need for secondary antiviral prophylaxis.
Viral load can be used to predict the potential risk for ganciclovir-resistant CMV disease. Using simple mathematical modeling, the efficacy of intravenous ganciclovir against susceptible wild-type CMV was found to be significantly higher than that against ganciclovir-resistant virus (91.5% [95% CI, 89 to 94%] versus 62% [95% CI, 57 to 66%]) (40). The persistence of CMV load despite sufficient treatment is the most common indicator of an-tiviral drug resistance (3, 201, 203, 204). Often, the virus popula-
tion during CMV disease is a mixture of wild-type and mutant viruses (40). Hence, one typically observes a decline in viral load during the initial phase of antiviral treatment, corresponding to the decline in the susceptible virus population. Thereafter, the drug-resistant virus predominates and becomes detected persist-
tently in the blood. The incidence of ganciclovir-resistant CMV infection in SOT recipients remains low, at less than 1% (205, 206). However, ganciclovir resistance should be suspected when (i) the viral load persists, plateaus, or rises during treatment; (ii) the patient is highly immunocompromised from use of lympho-
cyte-depleting agents; (iii) the patient is a high-risk CMV D+/R− SOT recipient; and (iv) there is a history of prolonged antiviral exposure, through either antiviral prophylaxis, preemptive ther-
rapy, or antiviral treatment (3). Lung transplant recipients are gen-
erally at higher risk of drug-resistant CMV than the other SOT populations (202, 207, 208).

Patients suspected to have infection due to drug-resistant virus should have viral genotype analysis to detect mutations in UL97 and UL54 to define the phenotype of ganciclovir resistance or possible cross-resistance to other antiviral drugs (foscarnet and cidofovir) (209–211). Laboratory testing for drug-resistant CMV was recently reviewed in this journal (209). The clinical impact of drug-resistant CMV is enormous, as it has led to high rates of tissue-invasive disease, poor allograft survival, and heightened pa-
ton mortality (201, 212). Treatment is very limited, and depend-
g on the genetic profile, one may use highly nephrotoxic drugs, such as foscarnet and cidofovir (for UL97-exclusive mutants), or off-label and investigational drugs, such as leflunomide, mariba-
vir, etermovir, and CMX-001 (201, 213–215).

CONCLUSIONS

CMV load testing has contributed to contemporary principles for the diagnosis, prevention, and treatment of CMV disease in the SOT population. CMV NAT assays are helpful clinically in assess-
ing the risk of disease, ensuring sensitive and rapid diagnosis, and monitoring therapeutic responses. Despite the large amount of published research data, the interpretation of viral load results remains highly complex. This is due to the heterogeneity of the SOT population, variability of the risks within each SOT group, differing patient immune profiles and immunosuppressive regi-
mens, and nonuniformity and lack of standardization among the many molecular assays used for CMV DNA detection and quantifi-
cation. Without standardized tests available across different laboratories, clinicians must establish assay- and institution-spe-
cific viral load thresholds, correlating to the test used, population tested, and disease characteristics present in any given medical center. The recently released WHO standard is a significant ad-
vance that will help to harmonize viral load reporting and assist the medical community in attaining the goal of standardized prac-
tice. However, there remain other variables that influence the viral load threshold. Reducing the variability of NAT assays will require a multifaceted approach to improving the performance and com-
parability of these tests. A better understanding of the variables involved should help us to better interpret the test results and, more importantly, better appreciate the complexity of our pa-
tients and the individuality that is needed for the management of every single transplant recipient.

REFERENCES

1. Beam E, Razonable RR. 2012. Cytomegalovirus in solid organ trans-
2. Razonable RR, Paya CV, Smith TF. 2002. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopo-
3. Razonable R, Humar A. 2013. Cytomegalovirus in solid organ trans-
sured by a CMV test calibrated to the WHO international standard is predictive of CMV disease resolution in transplant recipients. Clin. In-
6. Hayden RT, Yan X, Wick MT, Rodriguez AB, Xiong X, Ginocchio CC, Mitchell MJ, Caliendo AM. 2012. Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivar-
7. Freyer JF, Heath AB, Anderson R, Minor PD. 2010. Collaborative study to evaluate the proposed 1st WHO international standard for hu-
8. Bate SL, Dollard SC, Cannon MJ. 2010. Cytomegalovirus seropreva-
12. Suwansirikul S, Rao N, Dowling JN, Ho M. 1977. Primary and second-
407.
gavirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection. Transpl. Int. 23:506–513.


Valantine HA. 2004. The role of viruses in cardiac allograft vasculopa-


Landry ML, Ferguson D. 1993. Comparison of quantitative cytomela-


Gerna G, Furlone M, Baldanti F, Sarasini A. 1994. Comparative quantita-


183. van den Berg AP, van Son WJ, Haagsma EB, Klokampfer IJ, Teggzess


Raymund R. Razonable is Professor of Medicine at the College of Medicine at Mayo Clinic. He also serves as Chair of Transplant Infectious Diseases, Associate Chair for Faculty Development, Program Director of the Transplant ID Fellowship Program, and Associate Program Director of the Infectious Disease Fellowship Program in the Division of Infectious Diseases at the Mayo Clinic. Dr. Razonable’s clinical and research interests are infections in immunocompromised hosts. He has authored more than 150 peer-reviewed original and review articles and book chapters on these topics, and he has given numerous presentations at regional, national, and international meetings. He is the author of the American Society of Transplantation guideline for CMV in solid organ transplantation. Dr. Ra-

Randall T. Hayden is Director of Clinical and Molecular Microbiology and Member in the Department of Pathology at St. Jude Children’s Research Hospital, Memphis, TN. He joined the faculty there in 2000, following postdoctoral training in microbiology and molecular microbiology at the Mayo Clinic and in surgical pathol-

October 2013 Volume 26 Number 4 cmr.asm.org 727

Downloaded from http://cmr.asm.org on October 19, 2017 by guest